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In the central nervous system of mammals, the regeneration of axons after injury is 
limited. The reduced ability of neurite outgrowth can be attributed, in part, to the 
presence of inhibitor proteins enriched in myelin. The three major axon growth-inhibitory 
molecules include Nogo, the myelin-associated glycoprotein (MAG) and the 
oligodendrocyte-myelin glycoprotein (OMgp).  
Over the last three decades, a considerable amount of research has been devoted to 
investigating the signalling cascades involved in myelin-associated inhibition as well as 
the strategies to overcome this inhibition. Nevertheless, little is known about the 
physiological function of these inhibitors. In evolution, the myelin-associated inhibition 
of regenerating axons coincides with the refinement of the innate and adaptive immune 
system of higher vertebrates. We hypothesized that also the motile processes of microglia 
and astrocytes in the CNS white matter might be responsive to myelin inhibitors that are 
well positioned to provide a protective shield for the critical axon-glia junctions.  
In this study, it was shown that microglia and astrocytes purified from post-natal mouse 
brains express the receptor NgR1 and its co-receptors known to bind the myelin-
associated inhibitors. Furthermore, MAG, when presented by heterologous cells, led to 
microglial and astrocytic process outgrowth inhibition, while microglial processes also 
avoided recombinant MAG in stripe assays. The repelling effect of MAG was observed 
in the absence of the MAG Ig domains 4/5, was partially reversed in microglial cells 
lacking NgR1, and was fully reversed in the presence of the Rho-associated kinase 
inhibitor Y27632. By using in vivo two-photon confocal microscopy to image the spinal 
cord of anaesthetized mice, the motility and roaming behaviour of fluorescently labelled 
microglia at the paranodes and their processes was modulated by the presence of MAG. 
In the Plp1 null mouse, a model of Wallerian degeneration, the absence of MAG led to 
the formation of foamy microglial cells, indicating abnormal myelin phagocytosis. In two 
models of neuroinflammation (the experimental allergic encephalomyelitis and the 
response of lipopolysaccharide injection), the absence of MAG resulted in altered 
microglial behaviour. Surprisingly, soluble MAG, which is physiologically associated 
with myelin breakdown, induces a strong inflammatory microglial response in culture. 
These findings support a model in which MAG protects intact paranodal junctions from 
perturbation by motile glial processes, and directly or indirectly modulates the microglial 






Rapid nerve conduction is important for the function of the nervous system. The increase 
in the body size of vertebrates, along with the increasing complexity of their nervous 
system required an adaptation that would facilitate the fast action potential propagation. 
The evolutionary acquisition of myelin in vertebrates, along with the confinement of 
voltage-dependent sodium channels to the small gap — the node of Ranvier - allowed the 
fast “saltatory” conduction of action potentials (Hartline and Colman, 2007). Myelin is a 
highly specialized, compacted, multi-layered plasma membrane that enwraps axons with 
little or no cytoplasm between adjacent wraps. The cells that produce myelin with their 
cellular processes are Schwann cells in the peripheral nervous system (PNS) and 

















Figure 1. Myelination in the central and peripheral nervous system 
Oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system 
(PNS) form the myelin sheath that enwraps the axons. Between the multi-layered myelin sheaths, there are 
gaps, the nodes of Ranvier. Oligodendrocytes myelinate more than one axon, while Schwann cells are in a 
1:1 ratio with the axons. Note the presence of astrocytic processes around the nodes in the CNS (adapted 




The myelin composition is particularly unique; in contrast to other plasma membranes, 
myelin is a lipid-enriched membrane composed of 70% lipids and 30% proteins (Morell 
and Ousley, 1994). The major proteins in CNS myelin are the myelin basic protein MBP 
and the proteolipid protein PLP/DM20 (Krämer et al., 2001). The distribution of the 
myelin proteins is not uniform, but specialized in distinct domains. The nodes are flanked 
on either side by the paranodal domains where myelin loops form septate-like junctions 
with the adjacent axonal membrane. Next to the paranodes are the juxtaparanodal 
domains residing underneath the compact myelin and finally the internodes extending 
beneath the compact myelin. These domains have a distinct protein composition that 
serves their function (Poliak and Peles, 2003) (Fig.2). The myelin sheath itself can also 
be divided into categories, the internodal compact and the non-compact one with the 
compact myelin being the dominant type (Scherer and Arroyo, 2002). 
 
Figure 2. Myelin compartments 
Schematic representation of a longitudinal section of a 
myelinated axon around the node of Ranvier. The node, 
the paranode, the juxta-paranode and the internode are 
depicted. In the PNS (upper half), the Schwann cell 
microvilli contact the node, whereas in the CNS (lower 
half), perinodal astrocytic processes are in close 
proximity to the node. Septate-like junctions (SpJ) are 
formed between the paranodal loops (PL) and the axon. 
The juxtaparanode lies underneath the compact myelin 




Myelin is not only essential for the fast conduction of the action potential but also for the 
maintenance of axonal integrity, protection, survival and function (Griffiths et al., 1998; 
Lappe-Siefke et al., 2003; Yin et al., 2006). Several mouse lines deficient in 
oligodendroglial proteins show normal myelination, but secondarily develop axonal loss, 






2.2 Myelin-associated inhibition of axonal outgrowth 
Although myelin evolved as an advantage for the vertebrates, in higher vertebrates its 
presence in the injured central nervous system constitutes one of the major impediments 
for axonal regeneration along with the glial scar and the invading immune cells from the 
periphery ( Zurn and Bandtlow, 2006). Cajal was among the first to observe that the 
capability of axonal regeneration in the CNS is restricted (Ramon y Cajal, 1928). 
 
“Once development was ended, the founts of growth and regeneration of the axons and 
dendrites dried up irrevocably. In adult centers, the nerve paths are something fixed, 
ended, immutable. Everything may die. Nothing may be regenerated.” 
 
It took almost 60 years to prove that it is the CNS environment and not axon-intrinsic 
factors that is the source of axonal outgrowth inhibition (David and Aguayo, 1981; 
Schwab and Thoenen, 1985). It was hypothesized that breakdown products of myelin are 
responsible for the inhibition (Berry, 1982). Eventually, specific myelin proteins were 
described to be inhibitory for neurite outgrowth in vitro (Caroni and Schwab, 1988a). The 
proof that these proteins are inhibitory in vivo came when Schwab and colleagues showed 
that an antibody, i.e. IN-1, raised against CNS myelin fractions that contain the 35kD and 
250kD inhibitory proteins, could neutralize the non-permissiveness of CNS myelin and 
promote axonal outgrowth in vivo (Schnell and Schwab, 1990). From this early stage 
onwards, a lot of research was conducted to identify the proteins that make myelin 
inhibitory for axonal outgrowth and the underlying mechanisms. The major myelin-
associated inhibitors include Nogo, the myelin-associated glycoprotein (MAG) and the 
oligodendrocyte-myelin glycoprotein (OMgp) (Xie and Zheng, 2008). 
 
2.3 Myelin-derived inhibitors 
2.3.1 Nogo 
Historically, the first myelin protein fraction identified as having an inhibitory role, 
termed NI-35/250, was discovered 20 years ago (Caroni and Schwab, 1988). However, it 
would be another 10 years before the cDNA encoding NI-250 could be identified and 
named Nogo-A (Chen et al., 2000; GrandPre et al., 2000; Prinjiha et al., 2000). There are 




region, while Nogo-A has a unique N-terminal domain. These proteins belong to the 
Reticulon protein family based on sequence homology. They have an ER-retention motif 
and are mainly associated with the endoplasmic reticulum. The expression of Nogo-A 
(200 kDa) is mainly restricted to oligodendrocytes in adulthood, while there is also a 
neuronal expression during development. Nogo-B (55 kDa) is expressed in various 
tissues, while Nogo-C (25 kDa) is mainly expressed in muscle (Huber et al., 2002; Wang 
et al., 2002). All three isoforms contain two hydrophobic domains with the loop in 
between termed Nogo-66, which has axon outgrowth-inhibitory properties (Grandpre et 
al, 2000; Prinjha et al., 2000) (Fig.3). The amino-terminal domain of Nogo-A is also 
inhibitory for axonal outgrowth but does not involve the Nogo-66 receptor (Fournier et 
al., 2001; Oertle et al., 2003). The topology of the amino terminal of Nogo-A has been 
controversial. There have been two main proposals: one supporting the intracellular 
localization of the amino-terminal domain and the other an extracellular localization. We 
now know, however, that both orientations at least occur in cultured oligodendrocytes 









Figure 3. Schematic representation of Nogo-A, -B and –C 
All three isoforms share a common C-terminal domain that contains the two hydrophobic transmembrane 
domains (black), which are separated by a 66-amino acid-loop (green). These 66-amino acids are 
responsible for the neurite outgrowth inhibition. All Nogo isoforms also share also a common ER retention 
motif (orange). Nogo-A has an additional long N-terminal domain, which independently can also inhibit 
the outgrowth of neurites (amino-Nogo) (adapted from Grandpre et al., 2000). 
 
Since the discovery of Nogo and its inhibitory properties, a number of studies have 
revealed that Nogo-deficient myelin has reduced inhibitory properties in vitro (Kim et al., 
2003; Simonen et al., 2003; Zheng et al., 2003). However, the findings of the in vivo 
spinal cord injury studies of these mutants were less consistent and inconclusive. One 
group showed significant corticospinal tract (CST) fiber regeneration in the Nogo A/B 




tendency towards the regeneration of corticospinal axons with considerable variability 
between the mice analyzed (Simonen et al., 2003). However, a third group did not 
observe any enhanced CST axon sprouting or regeneration in neither the Nogo A/B nor 
the Nogo A/B/C mutant mice (Zheng et al., 2003). These differences between the results 
gained by the three groups failed to provide sufficient evidence of the predominant 
importance of Nogo in axonal regeneration, and the differences were mainly attributed to 
the different genetic backgrounds of the mice used in the different studies, the surgical 
techniques, the axonal tracing methods and the presence of additional inhibitors. 
Nevertheless, a number of studies using neutralizing agents, such as the IN-1 antibody 
and the NEP1-40 peptide, revealed recovery after spinal cord injury (GrandPre et al., 
2002; Li and Strittmatter, 2003; Liebscher et al., 2005). This discrepancy between the 
Nogo neutralizing agents and the knockout mice could be attributed to the general effect 
of the agents on more than one inhibitor and the time limitations for the emergence of 
compensatory mechanisms. 
 
2.3.2 Myelin-associated glycoprotein (MAG) 
MAG, also known as Siglec-4, was isolated as a CNS myelin constituent earlier than 
Nogo (Quarles et al., 1972; Arquint et al., 1987). It is expressed both by CNS and PNS-
myelinating glia with an approximately 10-fold higher abundance in CNS myelin and is 
localized in periaxonal regions (Quarles, 2007). MAG belongs to the superfamily of 
proteins with an Immunoglobulin-like domain and, more specifically, the siglec 
subgroup; it is a single transmembrane domain protein with a large extracellular fragment 
that contains five immunoglobulin-like domains and binds to sialic acid-containing 
oligosaccharides. This domain consists of eight glycosylation sites that are mostly 
complex and negatively charged because of sialic acid (Georgiou et al., 2004). There are 
two MAG splice isoforms, the short (S-MAG) and the long (L-MAG), which differ in 
their cytoplasmic domain (Tropak et al., 1988). The longer cytoplasmic domain of L-
MAG has been associated with intracellular signalling in the oligodendrocytes via the 
action of Fyn tyrosine kinase and phospholipase Cγ  (PLCγ) (Jaramillo et al., 1994; 
Umemori et al., 1994) (Fig.4). 
 
Despite the availability of knockout mice (Li et al., 1994; Montag et al., 1994), the 




periaxonal membrane led to the suggestion that MAG is implicated in axon-glial 
communication. In the absence of MAG, the mice exhibited subtle structural 
abnormalities in the periaxonal region, and the formation of compact CNS myelin was 
normal but slightly delayed (Montag et al., 1994). The phenotype was more severe in the 
PNS, where axonopathy proceeded with age (Yin et al., 1998). Overall, despite the subtle 
phenotype of the MAG-deficient mice possibly due to compensatory mechanisms, MAG 
was suggested to participate in a signalling system that is necessary for the maintenance 
and survival of some axons (Quarles, 2007). Further investigations are needed to fully 
understand the relative physiological importance of MAG, while a number of studies 














Figure 4. Structure of MAG  
MAG (yellow) has five extracellular immunoglobulin-like domains (circles), eight N-linked 
oligosaccharides (triangles), a single transmembrane domain and two alternative cytoplasmic domains (red 
for L-MAG and orange for S-MAG). MAG has been suggested to be involved in bidirectional signaling 
between oligodendrocytes and neurons, though little is known about the pathways involved. The 
extracellular domain may bind to neuronal gangliosides (green circular structures) or receptors, such as 
NgR1 and others (adapted from Quarles, 2007). 
 
The ability of MAG to inhibit axonal outgrowth is attributed to its extracellular domain 
and was discovered using myelin fractionation assays different than those used for Nogo 
(McKerracher et al., 1994; Mukhopadhyay et al., 1994). Dependent on the developmental 




(adulthood) substrate for axonal outgrowth. It exerts its inhibitory activity by binding to 
the Nogo-66 receptor (NgR1) (Domeniconi et al., 2002; Liu et al., 2002). Interestingly, it 
was shown that it additionally binds to Nogo receptor 2 (NgR2) and with a higher affinity 
than to NgR1 (Venkatesh et al., 2005). MAG, as a siglec protein, binds also to neuronal 
gangliosides and especially to GD1a and GT1b (Yang et al., 1996). Most of the research 
regarding the MAG receptor has concentrated on the NgRs, and the involvement of 
gangliosides in inhibition had been controversial (Vinson et al., 2001; Vyas et al., 2002). 
However, a recent study revealed that different neuronal cell types could be inhibited by 
MAG via gangliosides and/or NgRs (Mehta et al., 2007). Although the MAG Ig domain 1 
is important for the sialic acid binding, this is not the domain that elucidates the 
inhibitory activity (Tang et al., 1997a,b), since the neurite outgrowth inhibitory domain 
was recently mapped to the Ig domain 5 (Cao et al., 2007). Interestingly, a proteolytic 
derivative of MAG consisting of its extracellular domain, namely dMAG, was detected in 
purified myelin (Sato et al., 1982; Stebbins et al., 1997) and the CSF of control and 
patients with neurological diseases (Yanagisawa et al., 1985). Interestingly, this MAG 
derivative has been shown to maintain its neurite outgrowth inhibitory properties in vitro 
(Tang et al., 1997a; 2001).  
 
2.3.3 Oligodendrocyte-Myelin glycoprotein (OMgp) 
OMgp is a glycosylphosphotidylinositol (GPI)-anchored protein that contains five 
leucine-rich repeat (LRR) domains. However, OMgp is not only expressed in 
oligodendrocytes but also in neurons (Habib et al., 1998). Later on, it was shown that 
OMgp also inhibits neurite outgrowth and binds to the same receptor as MAG and Nogo, 
the Nogo-66 receptor (Wang et al., 2002). Although it was previously believed to be 
present in compact myelin, it was more recently shown that it is localized in the 
membrane surrounding the nodes of Ranvier (Huang et al., 2005). Interestingly, OMgp-
deficient mice exhibited elevated axonal sprouting both in grey and white matter, 
suggesting a general role of OMgp in restricting axonal sprouting (Huang et al., 2005). 
Using an in vivo model of spinal cord injury, there was improved regeneration in OMgp-
deficient mice and less neurite outgrowth inhibition when myelin from OMgp-deficient 




2.3.4 Receptors for myelin inhibitors and downstream signalling  
All three main myelin-associated inhibitors, Nogo-A, MAG and OMgp, bind to the same 
Nogo-66 receptor (NgR1) despite the lack of sequence similarity (Fournier et al., 2001; 


























Figure 5. Schematic representation of the myelin-associated inhibitors in the CNS 
MAG, Nogo-A and OMgp are the three major inhibitors associated with the CNS myelin. They all bind to 
the same GPI-anchored NgR1 receptor, which recruits the co-receptors p75 neurotrophin receptor or Troy 
and additionally Lingo-1, to form a receptor complex that transduces the inhibitory signals downstream in 
neurons. MAG also binds to NgR2, the co-receptors of which have not been identified. In neurons, the 

















(ROCK), which will lead to further cytoskeletal rearrangements and neurite outgrowth inhibition. Nogo-A 
has two inhibitory domains: the Nogo-66 loop that binds to NgR1 and the amino-Nogo domain, which 
binds to an as yet unidentified receptor.  
 
NgR1 is a GPI-anchored protein, so it does not transduce the signal downstream unless it 
interacts with a transmembrane protein. Indeed, NgR1 recruits the p75 neurotrophin 
receptor (Wang et al., 2002; Wong et al., 2002) or alternatively Troy/Taj (Park et al., 
2005; Shao et al., 2005) and Lingo-1 (Mi et al., 2004) (Fig.5). More recently, the 
epidermal growth factor receptor (EGFR) has also been linked to the NgR1-ligand 
signalling but without any direct association with the NgR or the myelin-associated 
inhibitors (Koprivica et al., 2005). 
 
The intracellular pathway further involves RhoA, a small GTPase that alternates between 
a GDP-bound inactive form and a GTP-bound active form. This leads to Rho-associated 
kinase (ROCK) activation, further cytoskeletal rearrangements and finally neurite 
outgrowth inhibition (Liu et al., 2006) (Fig.5). The involvement of RhoA in myelin-
mediated inhibition was known before the discovery of the NgRs. It was shown that 
blocking Rho activation could eliminate the myelin-elicited inhibition in vitro (Lehmann 
et al., 1999) and in vivo (Dergham et al., 2002; Fournier et al., 2003). Another 
intracellular molecule involved is the protein kinase C (PKC) (Sivasankaran et al., 2004). 
Interestingly, elevated cyclic adenosine monophosphate (cAMP) was shown to overcome 
myelin-elicited inhibition and promote regeneration in vitro (Song et al., 1998; Cai et al., 
1999) and in vivo (Qiu et al., 2002).  
 
Although NgR1 was the first receptor discovered to bind the myelin-associated inhibitors, 
two homologues were identified later, the NgR2 and the NgR3 (Lauren et al., 2003; 
Pignot et al., 2003). Additionally, it was shown that MAG binds to NgR1 and NgR2, but 
not NgR3 (Venkatesh et al., 2005). However, the involvement of NgR1 in the myelin-
associated inhibition is dependent on the form in which these inhibitors are presented. For 
example, the acute exposure of MAG leads to NgR1-dependent neurite outgrowth 
inhibition, while chronic exposure is NgR1-independent (Chivatakarn et al., 2007). 
 
The importance of the NgR1 in the myelin-associated inhibition was assessed in vitro by 




protein and there was an increased neurite outgrowth in the presence of the myelin-
associated inhibitors (Li et al., 2004b; Fournier et al., 2002). To investigate the 
significance of NgR1 in vivo, different approaches were followed. On the one hand, the 
presence of NgR1 ectodomain acted as antagonist to the myelin inhibitory ligands and 
resulted in enhanced CST regeneration in rats and mice (Li et al., 2004a; 2005), while in 
an optic nerve crush model the effect was not the same (Fischer et al., 2004). The second 
line of research included the generation of NgR1-deficient mice (Kim et al., 2004; Zheng 
et al., 2005). The in vitro results of the two groups were contradictory regarding the 
improvement of neurite outgrowth from NgR1-deficient mice on myelin substrates. 
Additionally, both groups failed to show enhanced CST regeneration in a spinal cord 
injury model in vivo. Various reasons could account for the discrepancy between the two 
groups regarding the in vitro results, such as the different myelin preparation protocols or 
the ways it is presented as a substrate or the type of neurons tested (Mehta et al., 2007). 
Regarding the differences in regeneration for the antagonist approach and the genetic 
manipulation of the ligand-receptor interaction, it can be that compensatory mechanisms 
have the time to counteract during development, which is not the case when a substance 
is applied acutely. However, one important point is that other receptors, such as NgR2 
and PirB, might as well be involved in the myelin-associated inhibition (Venkatesh et al., 
2005; Mehta et al., 2007; Atwal et al., 2008). Nevertheless, at this point we may conclude 
that NgR1 is at least partially involved in the myelin inhibition of axonal outgrowth. 
 
2.3.5 Is there a physiological function of the myelin-associated inhibitors?  
The emergence of the myelin-associated inhibition of axonal outgrowth remains 
functionally unexplained, as poor regeneration offers no obvious evolutionary advantage. 
It has been hypothesized that the CNS, when expressing myelin-associated inhibitors in 
white matter tracts, may be protected from the effects of abnormal axonal sprouting 
(Raisman, 2004; Huang et al., 2005; Quarles, 2008). However, the mammalian peripheral 
nervous system, which regenerates, would not function well if abnormal sprouting was a 
persistent feature either. I am also unaware as to whether the abnormal sprouting of CNS 
axons is a tolerated feature of lower vertebrates in which the CNS axons can regenerate.  
Instead, it was noted that the occurrence of reduced regeneration in higher vertebrates 
coincides with the refinement of the innate and adaptive immune system (Popovich and 




the resident glial cells of the CNS, such as the microglia and the astrocytes. The word 
“glia” originates from the Greek word meaning glue, so these cell types were regarded as 
the glue that holds the CNS together. 
 
2.4 Microglia  
Microglial cells are the resident immune cells of the central nervous system (Kreutzberg, 
1996). Microglial research has been conducted for over 50 years and several review 
articles summarize the current knowledge regarding their function in the healthy CNS 
and under pathology (Perry and Gordon, 1988; Streit, 2001; 2002; van Rossum and 
Hanisch, 2004; Schwartz et al., 2006; Hanisch and Kettenmann, 2007). Here, I will only 
highlight the cell characteristics of microglia that are more relevant to the hypothesis of 
this work.  
 
Although the microglial origin has long been debated, it is currently believed that 
mesodermal glial cells invade the CNS parenchyma during embryonic development 
followed by the second entrance of bone marrow-derived monocytes during the postnatal 
period (Rock et al., 2004; Chan et al., 2007). Traditionally microglia were classified into 
two groups based on their morphology and status; the “resting” and the “activated” 
microglia (Fig.6A). The “resting” microglia have a ramified morphology with many and 
thin processes extending from the cell soma, while the “activated” ones have a round, 
amoeboid morphology and properties that make them acquire a phagocytic function, 
which in turn renders them indistinguishable from macrophages. The amoeboid phase is 
evident in early development during plasticity, while later on in adulthood microglia are 
in “resting” mode. Under any kind of pathology, the microglia react and become 
“activated”, not only by changing their morphology but also biochemically and 
metabolically so that they can cope with the homeostatic changes (van Rossum and 
Hanisch, 2004). However, a number of recent studies resulted in new terms, “resting” 
microglia are referred to as “surveying” and, upon receiving activation signals, microglia 
may acquire a diverse response phenotype and be termed “effector” microglia (Hanisch 









Figure 6. Microglial morphology 
Microglia are ramified in the “resting” state and, 
upon receiving pathological signals, they 
become “activated”. This change coincides with 
a change in their morphology; microglia become 
amoeboid. A number of recent studies have 
changed the simplistic view of microglia 
between the two main stages (A) into a more 
complex scheme (B). In the latter case, cells 
have distinct reactive phenotypes constituted by 
transcriptional and non-transcriptional changes. 
The reactive behaviour may change as the 
activating signals fade. The outcome can vary 
from cell death to retransformation to the 
“resting” phenotype (adapted from Kettenmann, 
2007; Hanisch and Kettenmann, 2007). 
 
 
The distinction of the microglial morphologies and the activating signals is more 
complicated. The microglial morphology and density varies in the different regions of the 
CNS; in the grey matter, microglial cells have a more stellate morphology while in white-
matter areas their processes are arranged more linearly. The number and nature of the 
molecules and conditions that can trigger the microglial activation is also variable. These 
signals could be termed as “on” and “off”, but in both cases this would lead to the 
microglial transformation in order to protect the CNS tissue (van Rossum and Hanisch, 
2004). The appearance of factors that are not usually present (such as microbial 
structures, viral proteins, serum components) or changes in their concentration 
(intracellular components) or in their presentation format (soluble factors, aggregates), 
signal the emergence of “danger” or damage. That would be the “on” signal for the 
microglial activation. On the other hand, there is a constitutive calming (“off”) system, 
such as the CD200-CD200R and CX3CR1-CX3CL1 pairs or the neurotransmitter release, 
the disruption of which would signal and lead to microglial activation (Hoek et al., 2000; 
Cardona et al., 2006;  Pocock and Kettenmann, 2007). Upon activation, as their origin 
dictates, microglia express a variety of molecules, such as the major histocompatibility 




chemokines and others. Furthermore, microglial activation is crucial for the involvement 
of the adaptive immune system, as microglia are the key components for the recruitment 
of neutrophils, leukocytes and macrophages (Aloisi, 2001). Nevertheless, microglial 
activation is a double-edged sword, as it is generally beneficial and acts in a protective 
way, but chronic microglial activation leads to neuronal damage and accounts for the 
injury observed in certain neurodegenerative diseases, such as Parkinson’s disease and 
multiple sclerosis (MS) (Gao and Hong, 2008; Lassmann, 2008). 
 
The “resting” microglia were previously regarded as dormant cells. However, recent in 
vivo two-photon microscopy of transgenic mice expressing the enhanced green 
fluorescent protein (EGFP) under the CX3CR1 promoter revealed that microglia have 
highly motile processes that roam the intercellular space, extending and retracting in a 
highly dynamic way (Nimmerjahn et al., 2005; Davalos et al., 2005; 2008). Their somata 
remain stationary, while their processes constantly retract and rebuild, enabling the 
microglial surveillance of the brain parenchyma without perturbing the already glial-
neuronal structures. Upon activation, such as after a laser-induced lesion, the microglial 
process outgrowth targets the lesion site. One of the substances that seemed to “guide” 
the microglial process outgrowth was the release of adenosine triphosphate (ATP) at the 
site of the local injury (Davalos et al., 2005; Raivich, 2005). Nonetheless, little is known 
about what controls and restricts this microglial activity in the healthy CNS. If, as 
discussed above, the myelin-associated inhibitors/NgR signalling pathway plays a role in 
restricting neurite process outgrowth in a pathological situation post-developmentally, it 
is equally feasible that it plays a similar role in restricting microglial process outgrowth. 
Strikingly, the expression of NgR and some of the co-receptors is not restricted to 
neuronal cells, but is also present in microglial cells (Satoh et al., 2005, 2007). 
 
2.5 Astrocytes 
Astrocytes were first described by Camillio Golgi in 1871 as a novel cell type in the CNS 
characterized by long, numerous, star-like processes. Astrocytes originate from 
neuroepithelial cells that form the ventricular zone; these proliferate and give rise to 
astrocytes, neurons and oligodendrocytes (Horner and Palmer, 2003).  The abundance of 




human brain (He and Sun, 2007). In the course of vertebrate evolution, there is evidence 
of a relative expansion of astrocytes in comparison to neurons, implying an evolutionary 
advantage of animals with a greater number of astrocytes (Needergard et al., 2003).  
 
One of the markers commonly used to stain astrocytes is the intermediate filament glial 
fibrillary acidic protein (GFAP). The function of this protein remains unknown, while 
GFAP-deficient mice display abnormal white matter architecture and the blood-brain 
barrier integrity is disturbed (Liedtke et al., 1996). Astrocytes in mammals can be 
distinguished into two types: the fibrous and the protoplasmic. Fibrous astrocytes contain 
many filaments, have long and thin processes, and are mainly localized in the white 
matter. Protoplasmic astrocytes, on the other hand, are found in the grey matter, have 
shorter and thicker processes and are mainly associated with synapses. Despite the 
evident morphological and structural differences between protoplasmic and fibrous 
astrocytes, both types of cells share similar functions.  
 
Astrocytic processes contact the blood capillaries with the “end-feet”, playing a 
nutritional role in the CNS. Another major astrocytic function is the support of neuronal 
function by maintaining local ion concentrations, storing CNS glycogen, clearing 
neuronal waste and mediating in the uptake of neurotransmitters (Nair et al., 2008). 
Moreover, astrocytes support neurons by supplying neurotrophic factors (Dreyfus et al., 
1999). However, another interesting role of astrocytes is their involvement in the CNS 
immune responses. Although their origin is not linked to the hematopoietic cells, they 
exhibit immune functions. They express toll-like receptors (TLRs), act as antigen-
presenting cells (APCs) and produce a variety of cytokines and chemokines.  Astrocytes 
are also important for the signalling to the periphery as they secrete chemokines and 
cytokines and their end-feet contact the blood vessels (Dong and Benveniste, 2001). 
 
Upon activation, astrocytes up-regulate their expression of GFAP in a process termed 
“astrogliosis”, a term that has commonly been used as a marker for pathology in CNS 
diseases. The role of astrocytes in pathology can be dual. In MS, astrocytes are 
responsible for the breakdown of the blood-brain barrier (BBB), the recruitment of T 
cells, along with the axonal damage and the oligodendrocytic death through the secretion 
of cytokines. On the other hand, astrocytes promote remyelination by helping to clear 





proliferation and maturation (Williams et al., 2007). Astrocytes also have a beneficial and 
a detrimental role in the CNS after injury. They form a glial scar, which is thought to 
protect the fragile brain tissue from further destruction (Myer et al., 2006). On the other 
hand, the formation of a mechanically obstructive glial scar composed of astrocytes and 
connective tissue elements is partially responsible for the failure of neuronal regeneration 
within the CNS after injury (Fitch and Silver, 2008).  
 
Taken together, these studies suggest that the astrocytic morphology reflects and supports 
the astrocytic function or reaction in the healthy CNS and in pathology. Strikingly, 
astrocytes express the NgR and some of the co-receptors known to bind the myelin-
associated inhibitors in neurons (Satoh et al., 2005; 2007) and, in addition, their 
morphology and migration is regulated by the small GTPase Rho (Holtje et al., 2005). 
Therefore, we wanted to assess the possible role of the myelin-associated inhibitors in 
regulating the astrocytic behaviour.  
 
2.5 Aim of the study 
While the ability of myelin-associated inhibitors, including Nogo, MAG and OMgp, to 
cause neuronal growth cone collapse has been studied in detail, the physiological role of 
these myelin inhibitors has remained obscure. We hypothesized that the highly motile 
cellular processes of microglia and astrocytes might also be responsive to myelin 
inhibitors. These proteins are ideally localized to provide a protective shield around 
myelin and the critical axon-myelin junctions in CNS white matter tracts. The aim of this 
thesis was to assess the response of microglia and astrocytes to myelin-associated 
inhibitors in vitro and in vivo, focusing on MAG, a well known myelin protein, and the 
nogo-66 receptor as its binding partner, because for both proteins mutant mice are 
available as experimental tools. 
 
MATERIALS AND METHODS 
 
3. Materials and Methods 
3.1 Materials 
3.1.1 Kits, chemicals and protocol source 
All chemicals used were purchased from the Sigma-Aldrich and Merck unless stated 
otherwise. All molecular biology kits were purchased from Qiagen, Promega and Sigma-
Aldrich, while cell culture and general laboratory material were purchased from Falcon, 
Nunc and Eppendorf.  
Websites for online protocols: 
http://mrw.interscience.wiley.com/emrw/9780471142720/home/ (Molecular biology) 
http://mrw.interscience.wiley.com/emrw/9780471140863/home/ (Protein Science) 
http://mrw.interscience.wiley.com/emrw/9780471142300/home/ (Neuroscience) 
3.1.2 Molecular biology buffers 
DNA-sample buffer (6x) 
20 % (w/v) Glycerol in TAE buffer 
0.025 % (w/v) Orange G or bromophenol blue 
 
dNTP-stock solutions (100 mM) 
25 mM each dATP, dCTP, dGTP, dTTP (Boehringer, Mannheim) 
 
Ethidiumbromide 
1-1.5 μg/ml for agarose gels in 1x TAE 
 
TAE (50x, 1000ml) 
2 M Tris-Acetate, pH 8.0 
50 mM EDTA 
57.1 ml Glacial acetic acid 
Add dH2O up to 1000ml  
 
TE (1x) 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
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Modified Gitschier buffer (MGB, 10x) 
6.7 ml 1 M Tris-HCl (pH 8.8) 
1.66 ml 1 M (NH4)2SO4 
650 μl 1 M MgCl2 
Add dH2O up to 10ml  
 
MGB buffer (1x, working solution) 
1 ml 10x MGB 
100 μl β-Mercaptoethanol 
500 μl 10 % Triton X-100 
8.4 ml dH2O 
3.1.3 Protein biochemistry buffers 
3.1.3.1 Lysis buffers 
Lysis buffer I (for brain) 
50 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 % Triton X-100 
1 mM PMSF (add before use) 
1 tablet Complete Mini protease inhibitor (Roche)/ 10 ml of lysis buffer 
* protease inhibitors are added freshly to the lysis buffer before use 
 
Lysis buffer II (for microglia) 
50 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 % Triton X-100 
1 % Nonidet P40 
0.1 % SDS 
1 tablet Complete Mini protease inhibitor (Roche)/ 10 ml of lysis buffer 
* protease inhibitors are added freshly to the lysis buffer before use 
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3.1.3.2 Protein purification buffers 
Wash buffer I (WB I) 
10 mM Tris, pH 7.5 
150 mM NaCl 
0.05 % Tween-20 
10 mM EDTA 
Adjust pH to 7.5 
 
Wash buffer II (WB II) 
50 mM Tris, pH 7.5 
 
Elution buffer I (EB I) 
0.1 M Glycine, pH 3.0 
 
Elution buffer II (EB II) 
0.1 M Glycine, pH 2.5 
 
Neutralization buffer (NB) 
1 M Tris, pH 8.0 
3.1.4 SDS PAGE and Western Blotting 
Separating SDS gel (12 %, 4 gels, 1.5 mm thickness) 
13 ml dH2O 
15 ml 30 % Acrylamide (BioRad, 29.1) 
9.4 ml 1.5 M Tris-HCl (pH 8.8) 
370 μl 10 % SDS 
125 μl 10 % APS (Ammonium persulfate) 
30 μl TEMED (BioRad) 
 
Stacking SDS gel (4 gels) 
6.1 ml dH2O 
1.3 ml 30 % Acrylamide (BioRad, 29.1) 
2.5 ml 0.5 M Tris-HCl (pH 6.8) 
100 μl 10 % SDS 
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50 μl 10 % APS (Ammonium persulfate) 
10 μl TEMED 
 
SDS running buffer (Laemmli buffer, 1x) 
25 mM Tris-HCl 
192 mM Glycine 
1 % (w/v) SDS 
 
SDS sample buffer (6x) 
7 ml 0.5M Tris-HCl buffer (pH 6.8) 
3 ml Glycerol (30 % final concentration) 
1 g SDS 
1.2 ml 1 % Bromophenol blue  
0.2 - 2 % β-Mercaptoethanol (add fresh) 
 
Transfer buffer (1x) 
48 mM Tris base 
39 mM Glycine 
10-20 % Methanol 
 
Blocking Buffer 
5 % non-fat dry milk powder in TBS or PBS (1x) 
 
Western blot stripping buffer 
0.2 M Glycine-HCl, pH 2.5 
0.1 % Tween-20 
 
Coomassie blue (Staining solution) 
2 g Coomassie brilliant blue (R-250) 
1 l Methanol 
200 ml Acetic acid 
800 ml dH2O 
Stir overnight and filter through Whatmann paper. 
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Destaining solution 
50 ml Methanol 
10 ml Acetic acid  
40 ml dH2O 
 
Tris buffered saline (TBS, 20x) 
1 M Tris base 
3 M NaCl 
Adjust pH 7.4 (with HCl) 
 
TBS with Tween-20 (TBST, 1x) 
50 mM Tris-HCl (pH 7.4-7.6) 
150 mM NaCl 
0.05 % - 0.15 % Tween-20 
3.1.5 DNA and Protein markers 
GeneRuler 1 kb DNA ladder (Fermentas) 
GeneRuler 100 bp DNA ladder (Fermentas) 
Precision Plus prestained protein standard (BioRad) 
3.1.6 Immunocytochemistry buffers 
Phosphate buffered saline (PBS) (1x cell culture, 1000 ml) 
136 mM NaCl 
2.6 mM KCl 
10 mM Na2HPO4 x2 H2O 
1.4 mM KH2PO4 
Set pH to 7.2 with 10 N NaOH 
Add dH2O up to 1000 ml  
 
4 % Paraformaldehyde in PBS/TBS 
100 ml 0.2 M NaH2PO4 (Sodiumdihydrogenphosphate)  
400 ml 0.2 M Na2HPO4 (di-Sodiumhydrogenphosphate)  
108 ml 37 % Formalin 
392 ml dH2O 
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Filtered with a 500 ml Nalgene sterile filter unit 
 
Blocking Buffer 
2 % BSA (Fraction V) 
2 % Goat serum 
0.02 % Biotin 
0.1 % Porcine skin gelatine 
0.01 % Saponin 
Dissolved in TBS or PBS 
 
Mounting Agent 
Aqua polymount (Polysciences) 
3.1.7 Immunohistochemistry buffers  
Phosphate buffer (stock solution) 
0.2 M NaH2PO4 
0.2 M Na2HPO4 
 
Phosphate buffer (working solution, pH 7.4) 
20 ml 0.2 M NaH2PO4 
80 ml 0.2 M Na2HPO4 
100 ml dH2O 
 
Bovine Serum Albumin (PBS/BSA) 
20 ml 0.2 M NaH2PO4 
80 ml 0.2 M Na2HPO4 
1.8 g NaCl 
1 g BSA 
100 ml dH2O 
 
Karlsson-Schultz (fixative solution for electron microscopy) 
20 ml 0.2 M NaH2PO4 
80 ml 0.2 M Na2HPO4 
1 g NaCl (0.5 % final concentration) 
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50 ml 16 % PFA (4 % final concentration) 
20 ml 25 % Glutaraldehyde (2.5 % final concentration) 
Add up to 200 ml dH2O  
Filter with a 500 ml Nalgene sterile filter unit 
 
Citrate Buffer (stock solution)* 
0.1 M Citric acid (C6H8O7*H2O) 
0.1 M Sodium citrate (C6H5O7Na3*2H2O) 
*Stored at 4°C 
 
Citrate Buffer (working solution, 0.01 M, pH 6.0)* 
9 ml 0.1 M Citric acid (C6H8O7*H2O) 
41 ml 0.1 M Sodium citrate (C6H5O7Na3*2H2O) 
450 ml dH2O 
*Always freshly prepared  
 
Tris Buffer (stock solution)* 
0.5 M Tris base 
Adjust pH 7.6 with HCl 
*Store at 4°C 
 
Tris Buffer (working solution)* 
100 ml 0.5M Tris base (pH 7.6) 
9 g NaCl 
Add up to 1000 ml with dH2O  
*Always freshly prepared  
 
Blocking buffer (2 % milk powder in Tris Buffer) 
20 g of non-fat milk powder  
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3.1.8 Histological stains and reagents 
Mayer’s Haematoxylin solution 
1 g Haematoxylin (Merck) was dissolved in 1000 ml dH2O and 0.2 g sodium iodate and 
50 g potassium aluminium sulphate (K2Al2(SO4)4*24H2O) was added under constant 
shaking. Finally, 50 g chloralhydrate and 1 g citric acid were added and the solution was 
filtered before use. 
 
Eosin solution 
Stock solution (10x)  
10 g of Eosin were dissolved in 100 ml of dH2O and left to mature. 
 
Working solution  
2.5 ml stock solution 
250 ml dH2O  
12 drops glacial acetic 
 
Scott’s solution 
2 g KHCO3 (potassiumhydrogencarbonate)  
20 g MgSO4 (magnesium sulphate)  
Add up to 1000 ml with dH2O  
 
HCl- Alcohol 
1.25 ml HCl 
350 ml Ethanol 




0.1g Eosin was dissolved in 100 ml dH2O and 0.1 g methylene blue in 100 ml dH2O. The 
two solutions were mixed and left for 3-4 days to mature. The solutions were filtered 
through Whatmann paper, let to dry over night and then dissolved in 10 ml pure 
methanol. The solution was stored at 4°C. 
Giemsa solution 
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Dissolve 1 g of Luxol blue (1B, MBS from Chroma) in 1000 ml 96 % ethanol while 
stirring and warming. Let the solution cool down at room temperature and filter though 
Whatmann paper. Before use, for every 100 ml of staining solution add 50 μl of 
concentrated acetic acid (CH3COOH). 
 
‘Nuclear fast red’ solution 
Dissolve 0.2 g of ‘nuclear fast red’ in 200 ml of boiling 5 % aluminium sulfate solution 
and boil for an additional 5-10 min. Let it cool down at room temperature and filter with 
Whatmann paper. 
3.1.9 Cell culture media 
DMEM for mammalian cell culture was purchased from GIBCO or BioWhittaker. 
3.1.9.1 Buffers and media for Primary Cell Culture  
Mixed glial and microglial culture medium 
DMEM, High glucose (4500mg/l) 
10 % heat-inactivated FBS 
1 % Penicillin/Streptomycin (Lonza) 
 
Hank’s Balanced Salt Solution (HBSS) for preparation of brains 
500 ml HBSS 
7.5 ml 10 % MgSO4 
 
Trypsin in HBSS 
Dilute stock trypsin 1:100 in HBSS 
Freeze aliquots at -20°C 
 
DNAse in HBSS (0.05 %) 
Dilute 100 mg in 200 ml HBSS, Freeze aliquots at -20°C 
 33
MATERIALS AND METHODS 
 
3.1.9.2 Buffers and media for Cell lines 
CHO medium 
DMEM, High glucose (4500 mg/l) and with 4 mM L-Glutamine 
10 % heat-inactivated dialyzed FBS 
34.8 mM L-Proline 
300 nM Thymidine 
10 mM Glycine 
 
3T3 Fibroblasts medium 
DMEM, High glucose (4500mg/l) 
10 % heat-inactivated FBS 
1 % Penicillin/Streptomycin 
 
Freezing Medium for CHO and 3T3 cells 
70 % DMEM, high glucose 
20 % FCS 
10 % DMSO 
3.1.10 Cell lines  
Mammalian cell lines 
CHO (Chinese Hamster Ovary cells) (gift from M.Filbin, Mukhopadhyay et al., 1994) 
• MAG-expressing CHO cells 
• Control-CHO cells 
3T3 Fibroblasts (kindly provided by M.Schwab, Dodd et al., 2005) 
3.1.11 Mouse lines 
MAG knock out (Montag et al., 1994) 
PLP knock out (Klugmann et al., 1997) 
NgR1 knock out (kindly provided by M. Tessier-Lavigne, Genentech, Zheng et al., 2005) 
CX3CR1-EGFP (Jung et al., 2000)  
Thy1-EYFP (Winter et al., 2007) 
GFAP-EGFP (kindly provided by F.Kirchhoff, MPIem, Goettingen) 
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3.1.12 Oligonucleotides 
Oligonucleotides were synthesized in the Max Planck Institute of Experimental 
Medicine. 
 






Amplification product: 600 bp for mutant and 300 bp for wild-type 
 
PLP 
Forward: 5’- GGAGAGGAGGAGGGAAACGAG -3’ 
Reverse: 5’- TCT GTT TTG CGG CTG ACT TTG -3’ 
Neo: 5’-TTGGCGGCGAATGGGCTGAC-3’ 
Amplification product: 300 bp for mutant and 150 bp for wild-type 
 
NgR1 
Forward: 5’- TCGGCACATCAATGACTCTCC-3’ 
Reverse: 5’- TATGTACACACACCTGGTGGC-3’ 
Neo: 5’-TGGGCTCTATGGCTTCTGAG -3’ 
Amplification product: 300 bp for mutant and 150 bp for wild-type 
 
3.1.12.2 Quantitative real-time PCR primers 
 
beta-actin 
Forward: 5’-CTTCCTCCCTGGAGAAGAGC-3’ Reverse: 5’-ATGCCACAGGATTCCATACC-3’ 
EGFR 
Forward: 5’-TCCATCCTAGAGAAAGGAGAGC-3’ Reverse:5’-TCAGCATCTATCATCCAGCACT3’ 
GFAP 
Forward: 5’-AGGGTGACAGCATTCTCTGC-3’ Reverse: 5’-CCGGTGGCTTGTTTCTCTTA-3’ 
Lingo-1 
Forward: 5’-AAGTGGCCAGTTCATCAGGT-3’ Reverse: 5’-TGGGCATGCTTCTCATACC-3’ 
Mac-1 
Forward: 5’-GAGCACCTCGGTATCAGCAT-3’ Reverse: 5’-CCCCAAAATAAGAGCCAATCT3’ 
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NgR1 
Forward: 5’-CGACCCCGAAGATGAAGAG-3’ Reverse: 5’-TGTAGCCATAACACCCATGC-3’ 
NgR2 
Forward: 5’-GAGGCTTGGTCAGCCTACAGT-3’ Reverse: 5’-CGCGAACAAGTCATCCTGT-3’ 
NgR3 
Forward: 5’-GCCCAGGGATTTGAATCT-3’ Reverse: 5’-AGCAGCAATTCCACACAG-3’ 
p75 
Forward: 5’-ACTGAGCGCCAGTTACGC-3’ Reverse: 5’-CGTAGACCTTGTGATCCATCG-3’ 
Troy 
Forward: 5’-AGGAGAGAAACCCGGCTTCTGT-3’ Reverse:5’AGAGGATTCTGCATCAGAGGCC3’ 
3.1.13 Antibodies  











Antibody Species Company Dilution Purpose 
Fcγ I R Rat R&D systems Series Block 
Fcγ III/II R Rat BD Pharmingen Series Block 
GAPDH Mouse Assaydesigns 1:1000 WB 
GFAP Rabbit Dako 1:400, 1:200 ICC, IHC 
GST Mouse Sigma 1:1000 WB 
Mac-1 Rat BD Pharmingen 1:1000 ICC 
Mac-3 Rat BD Pharmingen 1:500 ICC 
MAG Mouse Provided by J. Trotter 1:50 ICC 
MAG Sheep Provided by S. Kelm 1:500 ICC 
NgR1 Sheep Provided by S. Kelm 1:500 WB 











Antibody Species Company Dilution 
Alexa488-coupled anti rabbit/rat IgG  Goat M.probes 1:400 
Alexa568-coupled anti rabbit/rat IgG Goat M.probes 1:400 
Cy™3-coupled anti-mouse IgG Goat Dianova 1:1000 
Cy™3-coupled anti-rabbit IgG Goat  Dianova 1:1000 
Cy™2-coupled anti-rabbit/mouse IgG Goat Dianova 1:100 
Cy™3-coupled anti-sheep IgG Donkey Dianova 1:750 
FITC-conjugated streptavidin Goat Linaris 1:100 
HRP-conjugated anti-IgG-anti-mouse Goat Dianova 1:5000 
HRP-conjugated anti-sheep IgG Goat Dianova 1:5000 
HRP-conjugated anti-goat IgG Mouse Sigma 1:50000 
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3.1.14 Enzymes 
RedTaq DNA polymerase (Sigma) 
GST-3C PreScission protease (GE Healthcare 
3.2 Methods 
3.2.1 RNA isolation and quantification 
3.2.1.1 Small scale RNA purification (‘RNeasy mini prep’) 
Small-scale ‘RNeasy mini preps’ (Qiagen) were used to purify the total RNA from 
FACS-sorted microglia and astrocytes and primary microglia after LPS induction. The 
RNAs were purified following the manufacturer’s instructions. In brief, microglia in 
culture and FACS sorted microglia and astrocytes were lysed in RLT buffer and kept at -
20°C until further use. The samples were thawed quickly by incubating them at 37°C in a 
water bath and further homogenized by vigorous vortexing for 1 min. Ethanol was then 
added to provide the appropriate binding conditions, and the homogenates were applied 
to RNeasy mini columns where the total RNA binds to the membrane and the 
contaminants are efficiently washed away. An additional step of DNAase incubation was 
included to digest the genomic DNA contaminations. The RNAs were eluted from the 
column with 50 μl of RNase-free ddH2O. 
3.2.1.2 RNA precipitation 
2 μl of coloured DNA carrier were added to the 50 μl of RNA to bind to the RNA pellet 
and enable later visualization. After vortexing, 25 μl of 7.5 M NH4Ac were added and 
then 187.5 μl of 100 % pure ethanol was included in the RNA mixture. The RNA 
solution was centrifuged for 30 min at maximum speed with a table microcentrifuge. 
After discarding the supernatant, the pellet was washed with 100 μl of 70 % ethanol and 
the pellet was left to dry. All the steps were carried out at room temperature. 4 μl of 
RNase-free ddH2O was added to the pellet and put on ice for a further 15 min to dissolve.  
3.2.1.3 cDNA synthesis 
cDNA synthesis is based on the characteristic feature of eukaryotic messenger RNAs to 
harbour the defined polyadenylated tail on the 3′ end. First-strand cDNA was synthesized 
for quantitative RT-PCR. Total RNA was mixed with 2 μl of random 9amer (0.55 
pmol/μl) and 2 μl of oligo-dT (110 pmol/μl) primers. The mixture was heated to 70°C for 
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5 min and then incubated on ice for 2 min. 4 μl of 5x First-Strand buffer, 2 μl of 0.1 M 
DTT and 1 μl of 10 mM dNTPs were added to the mixture and the final volume was 
adjusted with dH2O to 19 μl. Finally 1μl of SuperScript™ III RT (200 units/μl) was 
added to complete the synthesis reaction mixture. This mixture was incubated in the 
thermocycler at 25°C for 10 min, then 50°C for 30 min, 55°C for 30 min and finally the 
reaction was terminated by heating at 70°C for 15 min and incubating it further on ice. 
The cDNA was used later as a template for amplification in PCR.  
3.2.1.4 Quantitative real-time PCR for mRNA expression 
For each gene expression assay, 5 μl of SYBR green master mix, 1 pmol of each forward 
and reverse primer pair, 1 μl of dH2O and 4 μl of cDNA mixture were mixed in a 96-well 
plate. Real-time PCR was carried out using the ABI Prism 7700 Sequence Detection 
System and SYBR Green Master Mix according to the manufacturer’s instructions 
(Applied Biosystems). The PCR reaction was carried out for 40 cycles in the following 
temperature conditions: 10 sec -95ºC, 25 sec - 60ºC and 35 sec -72ºC. The SYBR green 
fluorescence was read at the 72ºC stage. All reactions were carried out in triplicates. The 
relative quantity (RQ) of RNA with respect to the housekeeping genes (β-actin and DNA 
methylase I) was calculated using 7500 Fast System SDS software Ver1.3 (Applied 
Biosystems) and the Excel-based RT-PCR analysis software qBase (Hellemans et al., 
2007). The results were depicted as histograms of normalized RQ values with RQ value 
lower than 1. 
3.2.2 Protein biochemical methods 
3.2.2.1 Lysis of microglial cells 
Microglial cells were harvested in 300 μl Lysis buffer II 24 hrs after plating. The cell 
lysate was then incubated at 4ºC in a tilt rotator for 30 min and centrifuged at 4ºC for a 
further 15 min at maximum speed. The supernatant was collected, the protein 
concentration was measured and the protein solution was further precipitated. 
3.2.2.2 Lysis of brains 
3-4 month old NgR1 wild type and knockout mice were sacrificed by spinal cord 
dislocation and decapitated. The brains were removed and collected in 14 ml falcon tubes 
in Lysis buffer I. These were further homogenized using an Ultraturrax (T8) on the 
highest settings (20-30s). The brain lysates were incubated 20-30 min on ice, the 
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insoluble cellular debris were pelleted by centrifugation at 2000 rpm at 4ºC for 10 min 
and the supernatant was used for further analysis or stored at -70°C. 
3.2.2.3 Protein precipitation (Wessel and Fluge) 
150 μl of microglial protein solution was precipitated by adding 450 μl methanol and 
vortexing. After the addition of 150 μl CHCl3 and 300 μl dH2O, the protein solution was 
vortexed and centrifuged for 5 min at 9000 rpm. The protein pellet precipitates were 
present in the interphase between CHCl3/methanol+dH2O. The interphase was removed 
and 300 μl of methanol were added and mixed. The protein solution was further 
centrifuged at maximum speed for 10 min. The supernatant was removed and the pellet 
was air dried and further resuspended in the desired volume of sample buffer. 
3.2.2.4 Purification of recombinant MAG proteins 
The plasmids encoding the Fc chimera with the five N-terminal domains of MAG or the 
three N-terminal domains, MAG d1-5 and MAG d1-3 respectively, have been previously 
described (Kelm et al., 1994). These were stably transfected into CHO (Chinese hamster 
ovary) K1 or CHO Lec1 cells. Stable cell lines were established using selection with 
hygromycin B. Culture supernatants (kindly provided by S. Kelm) were collected and the 
protein chimeras were purified on a protein-A membrane absorber (Sartobind, Sartorius). 
All the steps were carried out at 4ºC. First, the pH of the tissue culture supernatants was 
stabilized through the addition of 1 M Tris (pH 7.5) at a final concentration of 10 mM. 
EDTA was then added to a final concentration of 10 mM to prevent iron precipitation, 
and finally sodium azide was added to a final concentration of 0.02 % to prevent bacterial 
growth. The tissue supernatants were then centrifuged for 15 min at 7800 rpm at 4ºC in a 
TI-45 rotor (Beckman Coulter Optima LE-80K) and another 45 min at 40.000 rpm. The 
supernatants were collected and further centrifuged in a fixed angle rotor (Eppendorf 
5804R, F34-6-38 rotor) at 11.000 rpm for 15 min. They were then filtered through a 0.22 
mm bottle-top filter to remove fine debris. The protein-A membrane absorber was 
equilibrated with 100 ml WB I. After passing through the supernatants, the absorber was 
washed with 100 ml WB I, followed by 100 ml WB II to remove any unbound proteins. 
The Fc-chimeras were eluted and collected as 0.5 ml fractions by applying EB I with a 20 
ml syringe. 75 μl of NB was immediately added in every fraction to neutralize the pH. 
The fractions with OD280> 0.05 were then pooled and the buffer was exchanged by using 
PD10 columns (Sephadex 25, GE Healthcare). Briefly, the columns were washed with 2 
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volumes of dH2O, then 0.1 N NaOH / 1 % SDS, a further 0.1 N HCl and finally dH2O 
and TBS. The protein solution was then applied to the column and another 3 volumes of 
TBS were used for washing. Fractions of 0.5 ml were collected and the procedure was 
repeated three times. The protein concentration was measured and the fractions of interest 
were pooled. The Fc portion was then cleaved by adding 50 μg of GST-3C protease 
(PreScission Protease, GE) and 2 mM of DTT. The digest was carried out over night at 
4ºC. Following the same procedure through the protein-A membrane absorber where the 
Fc portions were bound, the recombinant MAG proteins/3C protease mixture was 
purified. Furthermore, using a GSH column (Amersham), the GST chimera of the 3C 
protease was bound to the column while the flow-through contained the recombinant 
MAG proteins. The buffer of the protein solution was then exchanged following the 
procedure mentioned above and the samples were further concentrated using the 
centricon microconcentrators (Sartorius, M-50). The protein solutions were finally 
sterilized through 0.22 μm filters (Costar Spin). 
3.2.2.5 Quantification of protein concentration by Lowry assay 
The protein concentrations were determined using the Bio-Rad DC Protein Assay kit 
according to the manufacturer’s 'microplate assay' protocol. The working principle of the 
kit is similar to the Lowry assay (Lowry et al., 1951). The absorbance was measured at 
650 nm in a microtitre plate reader. The assay is based on the reaction of proteins with an 
alkaline copper tertrate solution and folin reagent, which leads to the loss of 1, 2, or 3 
oxygen atoms, producing one or several reduced species that have a characteristic blue 
colour with maximum absorbance at 750 nm. The colour development is primarily due to 
the amino acids tyrosine and tryptophan, and, to a lesser extent, cystine, cysteine and 
histidine (Lowry et al., 1951).  
3.2.2.6 SDS polyacrylamide gel electrophoresis 
The proteins were separated using the discontinuous SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) described by Laemmli (Laemmli, 1970). The glass plates 
and the 1 mm spacers were assembled according to the Bio-Rad instructions. The 12 % 
separating gel solution of acrylamide was prepared freshly and poured between the 
assembled glass plates. The top of the gel was covered with a layer of dH2O-saturated 
isobutyl alcohol and left to polymerize for 30 min at room temperature. After rinsing the 
isobutyl alcohol twice with dH2O, the freshly prepared stacking gel solution was added 
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and a 1 mm Teflon comb (10 or 15 teeth) was inserted into the layer of the stacking gel 
solution and left to polymerize. The chamber and the gels were assembled based on the 
manufacturer’s protocol. The protein lysates were diluted in 6x SDS sample buffer 
containing 1 % β-mercaptoethanol and heated for 5 min to 90°C. 5 μl of pre-stained 
Precision-plus (BioRad) was loaded on a well as a molecular weight standard. The gels 
run at 10 mA/gel of constant current until the bromophenol blue tracking dye entered the 
separating gel and increased to 15 mA/gel. The electrophoresis was terminated once the 
bromophenol blue had reached the lower end of the gel. The gel was removed and 
preceded for Coomassie staining or protein blotting. 
3.2.2.7 Coomassie staining 
The gels were fixed for 15 min in 25 % isopropanol / 10 % acetic acid and then briefly 
washed with dH2O. After incubation in the coomassie blue staining buffer overnight, the 
gels were incubated with the destaining solution and scanned with an UMAX Astra47000 
scanner. 
3.2.2.8 Western blotting (WB) 
Electrophoretic transfer 
Proteins were transferred from the SDS-gel onto a PVDF membrane 
(Amersham/Millipore, pore size 0.45 μm) by electrophoresis, as originally described with 
modification (Towbin et al., 1979). PVDF membranes were activated for 30 sec in 100 % 
methanol and further incubated in transfer buffer for 15 min. The gels, the Whatmann 
paper and the blotting pads were pre-soaked in transfer buffer for 15-30 min and further 
assembled according to the manufacturer’s protocol. Proteins were transferred at a 
constant voltage of 38 V and a maximum current of 275 mA for a 1.5 mm gel and for 
1.5-2 hrs at room temperature. 
 
Immunological detection of proteins on PVDF membranes 
After electrophoretic transfer, the membranes were blocked for 1 hr at room temperature 
in blocking buffer (5 % non-fat dry milk in TBS). The primary antibody diluted in 
blocking buffer was applied overnight at 4°C with constant gentle shaking. After three 
10-min washes in TBST (0.05 % Tween-20 in TBS), HRP-conjugated secondary 
antibodies were applied for at least 1 hr in blocking buffer, followed by three 10-min 
washes with TBST. The membranes were washed once with TBS before being exposed 
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using the Enhanced Chemiluminescence Detection kit (PerkinElmer) according to the 
manufacturer’s instructions (Western Lightning™, Western Blot Chemiluminescence 
Reagent Plus, PerkinElmer Life Sciences, Inc.). ECL photographic film (Hyperfilm™, 
Amersham Biosciences) was used to expose the membranes. The time of exposure varied 
depending on the signal intensity. To reprobe the same membrane with a second 
antibody, the membrane was incubated with stripping buffer for 1 hr at 60°C with 
rigorous shaking. After one wash with TBST, the membrane was incubated in blocking 
buffer for 30 min before probing with the second primary antibody. 
3.2.3 Cell cultures 
3.2.3.1 Primary microglial and astrocytic cultures 
Primary microglia and astrocytes were obtained from primary mixed glial cultures. Glial 
cell cultures were prepared from the total brains of newborn P0-P2 C57Bl/6 mice or 
NgR1-deficient mice (kindly provided by M. Tessier-Lavigne, Genentech, South San 
Fransisco; Zheng et al., 2005) as described previously (Giulian and Baker, 1986) with 
adaptations. In brief, the brains were removed under sterile conditions and the brain 
tissue carefully stripped of meninges and trypsinized (1x in HBSS, Lonza) for 5 min at 
37°C. The cell suspension was then triturated with a fire-polished Pasteur pipette in the 
presence of 0.05 % DNAase (Roche). The cell pellet was resuspended in 10 ml glial 
culture medium and plated onto poly-L-Lysine coated 75-cm2 tissue culture flasks (Nunc) 
at a density of three brains per flask. Cultures were incubated at 37°C in a humidified 
incubator containing 5% CO2 and 95% air with medium changes every 2-3 days. 
Microglial cells were harvested from these primary mixed glial cell cultures after 10-12 
days. The microglial cells were purified from the initial mixed culture by gentle manual 
shaking, taking advantage of their differential adhesive properties. Supernatants were 
collected and centrifuged at 800 rpm for 5 min and the microglial cell pellet was 
resuspended in microglial culture medium or DMEM only and plated on 6-well plates (1-
2 × 105 cells/well, RNA), 16-well tissue culture slides (Lab-Tek, Nunc) (1 ×104 
cells/well, microglia-CHO co-culture), 96-well plates (1.5 × 104 cells/well, ELISA), 13-
mm coverslips (3 × 104/coverslip, stripe assay) and 6 cm plates (0.5 × 106 cells, WB). 
The purity of these cultures was >95% as determined by Mac-1 and Dapi co-staining. 
After shaking the microglia, the flasks were washed with HBSS and incubated with 
trypsin for 15 min at 37°C. After shaking, the detached cells were collected and the 
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enzyme was inactivated by adding the FCS-containing glial medium. The cell suspension 
was centrifuged at 800 rpm for 5 min and the astrocytic pellet was then resuspended in 
glial culture medium and plated on 8-well tissue culture slides (Lab-Tek, Nunc) (2 ×104 
cells/well,). 
3.2.3.2 CHO and 3T3 cell culture 
CHO cells (control and MAG expressing, kindly provided by M. Filbin) were maintained 
in CHO medium containing 10 % FCS on 10 cm tissue culture dishes (Falcon). Cells 
were grown at 37°C in a 5 % CO2 atmosphere. For passaging, confluent plates were 
trypsinized (1x in PBS) shortly and centrifuged at 800 rpm for min. The pellet was 
diluted in 10 ml CHO medium and 1 ml of the cell suspension was added to 9 ml of 
medium and further plated. Cells were passaged once or twice a week depending on the 
experiments. The 3T3 cells (kindly provided by M. Schwab) were passaged and 
maintained as mentioned above for the CHO cells, but in the 3T3 medium. These cells 
needed to be more confluent when plated, so they were diluted 1:4 in every passage. 
3.2.3.3 Fluorescent-activated cell sorting (FACS) of microglia and astrocytes 
To increase the purity of microglia and astrocytes, brain microglia and astrocytes were 
sorted using transgenic animals that express EGFP under a cell type specific promoter. 
More specific, heterozygous CX3CR1-EGFP (‘green microglia’) and GFAP-EGFP 
(‘green astrocytes’) mice were used for FACS. The brains of newborn mice were 
prepared as previously described (section 3.2.3.1) until trypsin was added. The brains 
were incubated with 2 ml HBSS (containing Mg2+), 1 ml trypsin and 1 ml 0.05 % 
DNAase at 37°C for 10 min. The cell suspension was then triturated with a 10 ml pipette 
and incubated at 37°C for another 10 min. The same step was repeated with a 5 ml pipette 
and a glass Pasteur pipette. The cell suspension was then centrifuged for 10 min at 800 
rpm and the cell pellet was resuspended with 3 ml Mg2+-containing HBSS. After 
filtration through a nylon 40 μm cell filter (BD Falcon), the cell suspension was 
incubated with 80 μl of PI (stock 1 mg/ml, Sigma) and 4 μl Hoechst (stock 5 mg/ml, 
Sigma) at 37°C for 20-30 min. Propidium iodide (PI) intercalates into double-stranded 
nucleic acids; it is excluded by viable cells but can penetrate the cell membranes of dying 
or dead cells. Hoechst 33342 is also a non-toxic membrane-permeable dye that 
intercalates in the DNA and is used to stain living cells. 5 ml of HBSS were then added 
and the pellet resuspended in 10 ml of glial culture medium. The cell suspension was kept 
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on ice until it could be sorted in a BD FACSAria™ cell sorter with the right filters and 
based on the manufacturer’s instructions (BD Biosciences). 
3.2.3.4 Microglial and astrocytic process outgrowth assay 
To assess the MAG-mediated or Nogo-mediated inhibition of microglial and astrocytic 
processes, primary microglial cells and astrocytes were cultured on confluent monolayers 
of CHO cells that express recombinant MAG on their surface, on control-CHO cells 
(Mukhoparadhyay et al., 1994), or on 3T3 cells that express Nogo-A at the surface (Dodd 
et al., 2005). Briefly, 8- or 16-well Lab-Tek chambers were coated with poly-L-lysine for 
1 hr at 37°C and then with 25 μg/ml fibronectin (only for the CHO cells) for 2 hrs at 
37°C.  Confluent dishes of CHO and 3T3 cells were split and 300 μl or 150 μl of 25*103 
cell suspensions were plated in the 8- and 16-well chambers respectively. Monolayers of 
cells were established over a 24-hr period. Microglia and astrocytes were plated onto the 
CHO cell and 3T3 monolayers and cultured in DMEM. The Rho kinase inhibitor (20 μM, 
Y27632; Calbiochem) was directly added to the culture medium at the time of plating. 
Microglial supernatants were collected for ELISA and the co-cultures were fixed after 4 
hrs or 24 hrs for 10 min with 4% PFA. The microglial co-cultures were stained for the 
microglial marker Mac-1 and the astrocytic co-cultures were stained for GFAP following 
the procedure in the section 3.2.5. The expression of MAG in the CHO cells was 
regularly checked by staining with a MAG antibody. 
3.2.3.5 Quantitative analysis of microglial morphology 
In order to quantitatively assess the microglial process inhibition, microglial cells were 
imaged with a fluorescence microscope (Leica DMRXA) equipped with a water 
immersion 40x objective and a ProgResC14 camera system (Jenoptic, Jena, Germany). 
For each group, at least 100 microglial cells from 3 different wells were analyzed using 
the ImageJ software. The ramification index (=forming factor) was calculated using the 
following formula (Wilms et al., 1997): 
                      RI= 4π (cell area)/ (cell perimeter)2, 
where RI is the ramification index. The ramification index is 1 when the cell is perfectly 
circular (no processes), whereas extremely ramified cells have a ramification index of 0.  
Cells with more processes have a value close to 0, whereas cells with fewer processes and 
more circular morphology have a value close to 1. The mean and SEM of the ramification 
index was determined from three independent experiments. The statistical significance of 
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the differences between experimental groups was assessed by applying the Student’s t-
test using the GraphPad Prism software package. 
3.2.3.6 Stripe assay 
Silicon matrices (exclusively distributed by M. Bastmeyer, Zoology Institute, University 
of Karlsruhe, Germany) were used to produce stripe patterns of purified proteins as 
previously described (Vielmetter et al., 1990). Briefly, the matrices were placed onto 
13mm poly-L-Lysine coated coverslips and 100 μl of recombinant MAG protein solution 
or FITC-conjugated streptavidin (Linaris) with a concentration of 10 μg/ml was filled 
into the channel. After an incubation period of 1 hr at 37°C, the unbound protein was 
removed by washing it twice with HBSS. Microglia were plated at a density of 3 × 104 
cells/coverslip and left to settle for 30 min before the medium was replaced with new 
one. After 20-24 hrs, the cultures were fixed and stained for MAG and Mac-1 following 
the steps mentioned in the section 3.2.5. The experiments were analyzed based on section 
3.2.7. More than 150 microglial cells growing on PLL, MAG or streptavidin stripes were 
measured per experiment and the percentage of the total cell number growing on PLL, 
MAG or both was calculated. All experiments were carried out with a minimum of 2-3 
coverslips per condition and a minimum of three independent experiments. The mean ± 
SEM of the total cell percentage is presented and the statistical significance was assessed 
using a Student’s t-test. 
3.2.3.7 MAG as substrate and TLR agonists 
The TLR agonist experiments were performed to check whether the MAG-mediated 
microglial response interferes with the TLR-mediated response. For that reason, the 
MAG-expressing CHO cells and coverslips coated with recombinant MAG were used. 
The microglia-CHO co-cultures were prepared as described in section 3.2.3.4 and the 
TLR agonists were added simultaneously to the cell suspension as described below. The 
13 mm coverslips were pre-coated with PLL for 1 hr at 37°C. After a short washing step 
with dH2O, 100 μl of recombinant MAG protein (10 μg/ml in HBSS) was applied to the 
coverslip and left to dry at 37°C for 1 hr. The solution was removed and the coverslips 
were washed with HBSS to remove any unbound protein. The microglial cells were 
plated at a density of 2-3*104 cells/coverslip and fixed after 24 hrs. Different TLR 
agonists, such as MALP-2 (10 ng/ml, Alexis) as a TLR 2/6 agonist, Pam3SK4 (10 ng/ml, 
Alexis) as a TLR 1/2 agonist and LPS (1 ng/ml, Alexis) as a TLR 4 agonist, were diluted 
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in microglial culture medium and added at the time of plating. All experiments were 
carried out three times. 
3.2.3.8 Soluble MAG microglial assay and ELISA 
3.2.3.8.1 Soluble MAG microglial assay 
Microglial cells were cultured on 96-well plates in microglial culture medium for 24 hrs. 
The medium was then changed and 10 ng/ml, 100 ng/ml, 1 μg/ml and 10 μg/ml of soluble 
recombinant MAG proteins were added. Cytokine and chemokine release was assessed in 
the supernatants 20 h after stimulation. The Fc blockage experiment was carried out as 
mentioned above by pre-incubating the cells with 1 ng/ml, 100 ng/ml, and 10 μg/ml of 
anti-CD16/CD32 and anti-CD64 antibodies for 30 min prior to the addition of 1 μg/ml of 
recombinant protein and the respective anti-Fc dilution. The supernatants were collected 
after 18 hrs stimulation and analyzed by ELISA. 
3.2.3.8.2 ELISA (Enzyme-linked Immunosorbent assay) 
Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), KC (mouse equivalent of growth 
regulatory oncogene-α (GROα-CXCL1) and macrophage inflammatory protein-1α (MIP-
1α) were analyzed using mouse-specific antibody pairs and mouse protein standards 
designed for ELISA application in accordance with the manufacturer's instructions (R & 
D Systems, Minneapolis, USA). Briefly, the captured antibody was diluted to the 
working concentration in PBS without carrier protein. 100 μl of the diluted antibody were 
applied on a 96-well plate and incubated overnight at room temperature. After three 
washes with PBS / 0.05 % Tween-20, any residual washing buffer was removed by 
inverting the plate against clean paper towels. The wells were then blocked with 1% BSA 
in PBS for 1 hr at room temperature and then washed twice as mentioned above. The 
culture supernatants were then diluted and 100 μl of the diluted sample or standard was 
added to the well and incubated for 2 hrs at room temperature. The plate was washed as 
mentioned above and 100 μl of diluted detection antibody was added to each well and 
incubated for another 2 hrs at r.t. The wells were then washed twice with PBST and 100 
μl of diluted HRP-conjugated streptavidin was added to the well and incubated for 20 
min at room temperature in the dark. After two washes with PBST, 100 μl of substrate 
solution was added in each well and incubated for another 20 min in the dark. Finally, the 
reaction was stopped by adding 50 μl of stopping solution to each well and reading the 
plate at 450 nm. Stimulation with lipopolysaccharide (LPS) (1 ng/ml, Alexis) served as a 
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positive control. Cytokine amounts were normalized to LPS stimulation. All the 
experiments were carried out with a minimum of 6 wells per condition (n ≥ 6) and a 
minimum of three independent experiments. 
3.2.4 Animal handling 
3.2.4.1 Animal breedings 
MAG-deficient mice and PLP-deficient mice were bred into the C57BL/6 background 
using mice from the breeding colony of the Max Planck Institute of Experimental 
Medicine. From these breeding pairs, MAG*PLP double mutants and littermate control 
animals were obtained from the same colony. As previously shown, there were no 
differences between mag+/- and mag-/- mice (Fujita et al., 1998). Consequently, we used 
mag -/-, mag+/-plp-/Y and mag-/-plp-/Y mutants at the age of 13 months for our study. 
Transgenic CX3CR1-EGFP mice (Jung et al., 2000) were bred with transgenic Thy1-
EYFP (Winter et al., 2007) and MAG-deficient mice for two-photon laser scanning in 
vivo imaging. The CX3CR1*Thy1*mag+/+ and CX3CR1*Thy1*mag-/- mice were 3-4 
months old. Astrocytes were isolated for FACS analysis from transgenic GFAP-EGFP 
mice (Nolte et al., 2001). All experiments were in compliance with the animal policies of 
the Max Planck Institute of Experimental Medicine, approved by the German Federal 
State of Lower Saxony.  
3.2.4.2 Preparation of mouse genomic DNA for genotyping  
For the preparation of mouse genomic DNA for genotyping, 2-3 mm of tail were cut and 
placed in microcentrifuge tubes. 180 μl of 1x MGB and 20 μl of proteinase K (10 mg/ml) 
were added to each tube and incubated at 52ºC overnight with vigorous shaking. Once the 
tails were dissolved, proteinase K was heat-inactivated by incubating the DNA lysate at 
95ºC for 10 min. Then, the DNA lysate was centrifuged at 13.000g for 1 min to pellet all 
the undigested material and the supernatant was collected in fresh tube. 1-2 μl of this 
diluted DNA preparation was used for genotyping PCR amplification. 
3.2.4.3 Genotyping polymerase chain reaction 
PCR MAG k.o PLP k.o NgR1 k.o 
Tail DNA 1 μl 1 μl 1 μl 
Primer neo (10 pmol/μl) 1 μl 0.5 μl 0.4 μl 
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Primer forward (10 pmol/μl) 0.25 μl 0.5 μl 0.4 μl 
Primer reverse (10 pmol/μl) 1 μl 0.5 μl 0.4 μl 
dNTPs (2 mM) 2 μl 2 μl 2 μl 
Red Taq Buffer (10x) 2 μl 2 μl 2 μl 
Red Taq (Sigma) 1 μl 1 μl 1 μl 
dH2O 11.75 μl 12.5 μl 12.8 μl 
 
PCR-program MAG k.o PLP k.o NgR1 k.o 
95˚C 3 min 3 min 3 min 
66°C / 56°C / 62°C 66°C, 30 s 56°C, 30 s 62°C, 45 s 
72°C 60 s 60 s 60 s 
95°C 30 s 30 s 30 s 
Cycles 36 36 39 
66°C 60 s 60 s 60 s 
72°C 10 min 10 min 5 min 
4°C Pause Pause Pause 
 
3.2.4.4 LPS injections and EAE 
Wild type and MAG-deficient mice aged 2.5-3.5 months old were weighed and 15 mg of 
LPS (serotype 055:B5, Sigma) per kg of mouse weight was injected intraperitoneally. 
The mice were processed following the procedures in the sections 3.2.6.1 and 3.2.6.2. 
Experimental allergic encephalomyelitis (EAE) served as model of multiple sclerosis in 
rodents. The induction of EAE in wild type and MAG-deficient mice, the clinical scoring, 
the perfusion of the animals, as well as the embedding of the tissue were performed in the 
lab of P.Calabresi (Johns Hopkins University, USA). 
3.2.5 Immunocytochemistry 
Immunostainings were carried out at the time mentioned in the experiment. All steps 
were performed at room temperature. Microglia and astrocytes grown on CHO and 3T3 
monolayers and in the stripe assay were fixed for 10 min in 4 % PFA. The cells were then 
washed three times for 10 min with PBS and blocked in blocking buffer for at least 30-60 
min. Primary antibodies diluted in blocking buffer were applied for at least 1.5-2 hrs at 
room temperature. After three 10-min washes with PBS, fluorochrome-conjugated 
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secondary antibodies were applied for at least 45-60 min. After washing once with PBS, 
the cells were briefly incubated with 4',6-diamidino-2-phenylindole (Dapi) and further 
washed twice with PBS. The cells were finally rinsed in dH2O and mounted in 
AquaPolyMount (Polysciences, Warrington, PA) on glass slides. 
3.2.6 Histology and immunohistochemistry 
3.2.6.1 Perfusion and fixation of mouse tissue  
The mice were deeply anaesthetized by injecting 2.5 % avertin (0.017 ml per g of mouse 
body weight) intraperitoneally. After anaesthesia, the mice were washed with 70 % 
ethanol in the stomach and the skin was removed from the ventral side. A transversal cut 
was made just below the diaphragm and slowly opened until the heart was visible. A new 
needle (27 gage) was inserted into the left ventricle and, immediately after starting the 
perfusion, a small incision was made in the right auricle to allow the blood to flow out of 
the body. Perfusion was carried out with HBSS and changed from HBBS to fixative (4 % 
PFA in PB for paraffin embedded tissue or Karlsson-Schultz for electron microscopy). 
The perfusion was carried out with 30-50 ml of fixation solution. The brain and the spinal 
cord were removed carefully and collected into vials with cold perfusion buffer. The 
tissue samples were stored in 4 % PFA overnight at 4°C and then in 1 % PFA until 
further use. 
3.2.6.2 Paraplast impregnation and embedding of the tissue 
After post-fixation, the tissue was washed 3-4 times with PBS. The brains were cut into 
half and pieces of different regions of the spinal cord were transferred into plastic 
chambers for dehydration and paraplast impregnation. The following steps were carried 
out before tissue embedding: 50 % ethanol for 1 hr, twice in 70 % ethanol for 2 hrs, twice 
in 96 % ethanol for 1 hr and twice in 100 % ethanol for 1 hr each. Then, the 100 % 
ethanol was replaced by isopropanol for 1 hr, twice in xylene for 2 hrs and the tissues 
were impregnated with paraplast at 60ºC for 2 hrs. Finally, the tissue was embedded in 
molten paraplast and left to harden.  
3.2.6.3 Haematoxylin-Eosin (HE) staining 
5-7 μm thick sections were cut from the paraffinized block using a microtome. The 
sections were floated on a warm water bath (42°C), placed on positively charged glass 
slides and then dried overnight at 37°C. The sections were then incubated at 60°C for 10 
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min before being deparaffinized and rehydrated in the following steps: twice in xylol and 
once in xylol/isopropanol (1:1) for 10 min, 100 %- 90 %- 70 %- 50 % alcohol for 5 min 
and finally dH2O. The sections were incubated with 0.1 % haematoxylin for 5 min 
staining the basic cell nuclear compartment blue. Following a wash with dH2O, the 
sections were dipped in HCl-alcohol solution once for 5-10 sec and then in Scott’s 
solution for 5 min. They were briefly rinsed with dH2O, counterstained with 0.1 % eosin 
for 3-5 min and then rinsed with dH2O. Sections were dehydrated by incubating them in 
an increasing alcohol concentration (50 %, 70 %, 90 %, and 100 %) for 2 min, then in 
xylol/isopropanol (1:1) and twice in xylol for 5 min. Finally, they were mounted with 
‘Eukitt’ (Kindler GmbH). 
3.2.6.4 DAB-based immunodetection on paraffin sections 
The sections were processed as above (section 3.2.6.3) until rehydration. The sections 
were then incubated for 5 min in citrate buffer before being ‘cooked’ for 10 min in 
boiling citrate buffer (at 650 watts in microwave oven). After this, the sections were left 
in the citrate buffer for about 20 min to cool down and subsequently rinsed in Tris buffer/ 
2 % milk for 5 min. Endogenous peroxidases were inactivated by incubating the sections 
with 100 μl of 3 % hydrogen peroxide for 5 min. Next, the sections were incubated with 
100 μl of goat-serum diluted in PBS/BSA (1:5) for 20 min at room temperature before 
proceeding with the 100 μl of the primary antibody diluted in PBS/BSA. After an 
overnight incubation at 4°C, the sections were washed with Tris buffer/2 % milk and 
incubated with 100 μl of bridging antibody, i.e. biotinylated secondary antibody (Dako) 
for 10 min. They were then rinsed with Tris buffer/2 % milk and probed with 100 μl of 
tertiary antibody, i.e. Horseradish Peroxidase streptavidin complex (Dako), by incubating 
the sections for 10 min. They were then rinsed with the Tris buffer and incubated with 
100 μl of DAB for 10 min. Finally, the sections were rinsed twice with dH2O for 5 min 
each and counterstained for 30 sec with haematoxylin following the steps until mounting 
(section 3.2.6.3). The enzymatic reaction between the HRP and DAB yielded a very a 
stable brown precipitate that was visualized under the microscope (section 3.2.7). 
3.2.6.5 May-Giemsa 
The sections were processed as above (section 3.2.6.3) until rehydration. They were then 
washed twice shortly in 100 % methanol before incubating with the staining solution for 
30 min. The sections were then washed shortly with dH2O before being incubated with 
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the Giemsa solution for 30 min. After a short wash with dH2O, the sections were dipped 
in 1 % acetic acid, washed with dH2O and dehydrated as mentioned above (section 
3.2.6.3). 
3.2.6.6 Luxol-Fast-Blue and ‘nuclear fast red’ 
The sections were processed as above (section 3.2.6.3) until rehydration. They were then 
incubated overnight in the LFB solution at 56°C. After cooling down, the sections were 
washed briefly with 96 % ethanol, then dH2O before incubating in 0.1 % lithium 
carbonate. After a brief wash in 70 % ethanol and dH2O, the sections were incubated for 
5 min in the ‘nuclear fast red’ solution and then washed with dH2O. The sections were 
subsequently dehydrated and mounted as mentioned above (section 3.2.6.3). 
3.2.6.7 Semithin sections 
The mice were anaesthetized and perfused with Karlsson-Schultz solution as mentioned 
above (section 3.2.6.1). The spinal cords were removed and post-fixed in 4% PFA for 16 
hrs and further contrasted with osmium tetraoxide before being embedded in epoxy resin 
(Serva). Semithin sections (0.5 μm) were cut at comparable levels using a microtome 
(Leica, RM 2155) with a diamond knife (Histo HI 4317, Diatome). The sections were 
then stained with methylene blue-Azur II for 1 min at 60°C and mounted with Eukitt.  
3.2.7 Light and Fluorescent Microscopy 
The light and fluorescent microscopic observation was performed with an oil immersion 
100x, 63x and 40x lenses and air 20x lenses (Leica, DMRXA) in the different 
experiments and the microscope was equipped with a ProgResC14 camera system 
(Jenoptic, Jena, Germany). The images were digitalized, analyzed and processed using 
Image J software (http://rsbweb.nih.gov/ij) and Photoshop 7.0.1. 
3.2.8 Two-photon laser scanning in vivo microscopy 
3.2.8.1 Anaesthesia and surgery 
The experiments (n>3 per genotype) were carried out with 12-16-week-old mice. A 
general anaesthesia was initiated by injecting 77 mg pentobarbital sodium i.p. (dissolved 
in 0.9 % NaCl solution) per kg of body weight. The anaesthesia was continued with 40-
60 mg per kg and methohexital sodium (Brevimytal Lilly). The mice were supported by 
artificial ventilation. The spinal cord segments L4 and L5 were exposed by a 
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laminectomy of the L1 and L2 spines for the imaging of the dorsal white columns. The 
animals were paralyzed with pancuronium bromide (Pancuronium Organon) to avoid any 
movement induced by active respiration during imaging. The spinal column was rigidly 
fixed with custom-made clamps. In all experiments, the exposed spinal cord was 
continuously superfused by ACSF. The body temperature was measured rectally and 
maintained between 36 and 38°C by a heated support.  
3.2.8.2 Two-photon laser scanning microscopy and image acquisition 
A two-photon laser scanning microscope (2P-LSM, Zeiss Axiocope 2 with LSM510 
NLO scanhead) equipped with an infrared fs-pulsed Ti:Sa laser (Mira 900/10 W Verdi; 
Coherent, Glasgow, UK) and a 40x (NA 0.8) or 20x (NA 1.0) water immersion objective 
was used for the acquisition of high resolution images. The laser was set at 895±5 nm for 
the simultaneous excitation of EGFP and EYFP. The emitted light was split by a 520 nm 
longpass dichroic mirror (Semrock, Rochester, USA) and collected by photo-multiplier 
tubes (Hamamatsu, Japan) through two bandpass filters, a 500±12 nm and a 542±27 nm, 
respectively (Semrock). Parallel, uniformly spaced (1.5 to 2 µm) planes of 400*400 to 
600*600 µm2 regions of the dorsal columns were recorded, digitized and processed to 
obtain z-stacks of images. The total acquisition time for a stack of 16 to 24 images was 
approximately 30-60 s. Several stacks were taken continuously to obtain a time-lapse 
series of microglial movement. 
3.2.8.3 Image processing and analysis 
The images were processed and the analysis was performed using the Zeiss LSM 
software and the ImageJ software. Prior to any analysis, the time series of the image 
stacks were corrected for the shifts in the horizontal and vertical directions by using an 
autocorrelation based custom-made software written in Matlab (v.7). In the majority of 
images, the median filter of ImageJ was used to remove any speckle-like noise. The 
EGFP and EYFP signals could be separated by choosing the right filter sets that 
permitted an unambiguous discernment of EGFP-expressing microglia from EYFP-




4.1 Microglial cells and myelin-associated inhibitors 
4.1.1 Microglial cells express the Nogo-66 receptors and co-receptors 
The myelin-associated inhibitors, i.e. MAG, Nogo-A and OMgp, bind to the same 
neuronal receptor, NgR1 (Liu et al., 2006). Additionally, it was shown that MAG also 
binds to the NgR2 and NgR3 receptor (Venkatesh et al., 2005). The expression of these 
receptors and the co-receptors that mediate myelin-associated inhibition has not been 
previously shown in isolated microglial cells. To test the expression of these receptors in 
microglia, microglial cells were purified from postnatal transgenic mice that express the 
enhanced green fluorescent protein (EGFP) under the microglial CX3CR1 promoter 
(Jung et al., 2000) (Fig.7A). The FACS isolated EGFP-positive microglia were analyzed 
with quantitative RT-PCR for the expression of the receptor complex that is known to 
mediate the inhibition by myelin in neurons (Fig.7B). Indeed, at the mRNA level the 
isolated microglia expressed all three homologues of the Nogo-66 receptor, i.e. NgR1, 
NgR2 and NgR3. Additionally, microglia expressed the co-receptors Lingo-1, EGFR and 
Troy, but not the low-affinity neurotrophin receptor p75. At the protein level, lysates 
from microglia cultured for 24 hrs were positive for the NgR1 (Fig.7C). These results 
show for the first time that the receptors and co-receptors involved in the myelin-
associated axonal inhibition are also expressed in microglia and are in agreement with 
previous studies showing the presence of some of these receptors at the histological level 
in microglia (Satoh et al., 2005; 2007) and in macrophages, their counterparts in the PNS 
(Fry et al., 2007). 
 
Microglia can be categorized based on their functional state in: i) ‘resting’, displaying a 
ramified morphology and weakly expressing molecules such as MHC II antigens, CD11c, 
CD40 and CD80 co-stimulatory molecules; or ii) ‘activated’, displaying a more round 
proliferative morphology and exhibiting regulation in the expression of these and other 
molecules (Ponomarev et al., 2005). Therefore, I examined whether the expression of 
these receptors is regulated dependent on the functional state of microglia. To this end, 
microglia were stimulated with lipopolysaccharide (LPS), a substance in the Gram-
negative bacterial cell wall that is known to activate microglia both in vivo and in vitro 
(Häusler et al., 2002; Kloss et al., 2001). Microglial cells were plated for 24 hrs before 
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being stimulated with LPS (0.1 ng/ml) for another 24 hrs. The microglia were then 
stained with Mac-1, a marker raised against the α chain of the complement receptor 3 
(CR3). The staining revealed the presence of ‘resting’ microglia that exhibited a ramified 
morphology with long and thin processes extending from their relatively small somata 
under non-stimulatory conditions (Fig.8Aa). After LPS stimulation, microglia were 
activated showing a more flat, round morphology with less and shorter extending 
processes and an increase in their soma size (Fig.8Ab). The mRNA expression profile 
analysis revealed an up-regulation of NgR1 and Lingo-1 expression, a down-regulation of 
NgR3, Troy, p75 and EGFR, and no change in the NgR2 expression (Fig.8B). These data 




























































Figure 7. Microglial expression of the Nogo-66 receptors (NgRs) and co-receptors 
A) Newborn P8-P10 heterozygous transgenic CX3CR1-EGFP mice were employed for FACS to isolate 
brain microglia in high purity. The EGFP-positive microglia could be clearly distinguished and isolated 
(window P6) from the total brain lysate. 
B) The RNA from the FACS-sorted microglia was isolated, reversely transcribed, and the resulting cDNA 
was used for the quantitative RT-PCR expression profile of the NgRs and co-receptors. Beta-actin was used 
for standardization. Microglia expressed the NgR1 and the two homologues NgR2 and NgR3. The co-
receptors Lingo-1, Troy and EGFR were also detected at the mRNA level but not the low-affinity 
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neurotrophin receptor p75. Mac-1 expression served as a microglial marker. The data represent the mean ± 
SEM of triplicates. 
C) Mouse brain microglia (Mg) were cultured for 24 hrs and a western blotting analysis revealed the 
expression of the NgR1 at the protein level. Total brain lysates from wild-type and NgR1-deficient mice 
















































Figure 8. Microglial expression of the Nogo receptor complex after LPS stimulation 
A) Mouse brain microglia cultured for 24 hrs on poly-L-lysine were visualized with immunoreactivity for 
the mouse αMβ2 integrin using the species-specific monoclonal antibody Mac-1. After 24 hrs, the microglia 
had several thin processes (arrows) and were ramified (a). A 1-day stimulation with LPS (0.1 ng/ml) led to 
microglial activation and a change in their morphology. Most of the microglia had shorter and thicker 
processes, while others adopted a round flat shape (dashed arrows) (b). Scale bars, 10 μm. 
B) Quantitative RT-PCR expression analysis of the NgRs and co-receptors in the absence or presence of 
LPS stimulation revealed differences between the two culture conditions. There was an up-regulation of 
NgR1 and Lingo-1 and down-regulation of NgR3, Troy, p75 and EGFR. The expression of Ngr2 was not 
altered. The data represent mean values ± SEM. 
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4.1.2 Microglial process outgrowth is inhibited by MAG 
The expression of the Nogo receptor complex in microglia implies a potential impact of 
the myelin-associated inhibitors on microglia. To test this hypothesis, an assay similar to 
the ‘neurite outgrowth assay’ described for neurons was employed (Mukhoparadhyay et 
al., 1994). Briefly, monolayers of CHO cells stably expressing MAG at the surface 
(Fig.9B), control-CHO cells, and Nogo-A-expressing 3T3 cells were established before 






















Figure 9. Microglial process outgrowth assay 
A) A schematic figure of the microglial process outgrowth assay. Control and MAG-expressing CHO 
cells or Nogo-A-expressing 3T3 cell monolayers were established overnight. Microglia were plated on the 
monolayers and, after 4 hrs or 24 hrs, the co-cultures were fixed and stained. 
B) Epifluorescence micrographs of MAG-expressing cell layers stained with anti-MAG and the nuclear 
marker Dapi. Scale bars, 20 μm. 
 
Microglia isolated from wild-type mice were plated for 24 hrs on confluent monolayers 
of CHO and 3T3 cells. Microglia on top of control-CHO cells had a bipolar and often 
bore more processes (processed morphology), while, when cultured on the MAG-CHO 































Figure 10. Microglial process outgrowth inhibition by myelin-associated glycoprotein 
A) Microglia isolated from wild type P0-P2 mixed glial cultures were cultured on confluent monolayers of 
control or MAG-expressing CHO cells and Nogo-A-expressing 3T3 cells. The co-cultures were fixed after 
24 hrs and stained for the αMβ2 integrin using the species-specific monoclonal antibody Mac-1. Microglia 
had a ramified and bipolar morphology when cultured on control-CHO cells, while they became more 
round and less processed when cultured on MAG-CHO cells. The microglial processes were not inhibited 
in the presence of Nogo-A-expressing 3T3 cells. Scale bars, 10 μm. 
B) The microglial morphology was determined using the ramification index (RI=4π (cell area/cell 
perimeter2)). This equation gives a value closer to 0 when the microglial cells bear more processes (more 
ramified) and values closer to 1 when the cells have fewer processes (more amoeboid). Microglial 
processes were inhibited by MAG, as microglial cells had a significantly higher RI on MAG-CHO cells 
(0.39±0.009) than on control-CHO cells (0.27±0.006). All the results represent the mean ramification index 




C) The supernatants of the microglial-CHO and microglial-3T3 co-cultures were analyzed with ELISA for 
chemokines and cytokines and compared with microglial cells plated on poly-L-lysine (PLL). There was no 
release of IL-6 and low release of MIP-1α and TNF-α, which is not a sign of microglial activation. The 
data represent mean values ± SEM of technical triplicates. Similar results were acquired from 3 
independent experiments. 
 
Interestingly, microglia had a ramified morphology when co-cultured with the Nogo-A-
expressing 3T3 cells, indicating that Nogo-A does not or only partially inhibits microglial 
process outgrowth. Notably, microglia were more ramified on top of the 3T3 cells 
compared to the control-CHO cells (Fig.10A), suggesting that other molecules expressed 
at the surface of these cell lines might influence the microglial morphology and status. 
The microglial morphological changes were quantified by the ramification index (RI); 
this is a ratio between the cell surface area and the cell perimeter, giving a value between 
0 and 1 dependent on whether they have more processes (more processed morphology) or 
they are more round (less processed morphology) respectively. Microglia plated on 
MAG-CHO cells had a significantly increased mean RI (0.39±0.009) compared to 
control-CHO co-cultures (0.27±0.006), indicating a less processed morphology 
(Fig.10B). In order to exclude the possibility that microglial process retraction was due to 
MAG-mediated microglial activation, the supernatants of the co-cultures were tested for 
cytokine and chemokine release (Fig.10C). Microglia plated on poly-L-lysine were used 
as a control. The profile of TNF-a, IL-6 and MIP-1a revealed a release that was 
undetectable or in low amounts, supporting the lack of microglial activation when co-
cultured with CHO or 3T3 cells. Taken together, these data illustrate that MAG and not 
Nogo-A act as an inhibitor of microglial process outgrowth in vitro. 
 
4.1.3 MAG-mediated microglial process inhibition is NgR1 and Rho-A dependent 
The molecular mechanism, which leads to neuronal growth cone collapse after 
encountering MAG, involves the binding to the NgR1 receptor and the co-receptors and 
downstream activation of RhoA signalling (Fournier et al., 2003; Mahta et al., 2007; 
Vinson et al., 2001). Therefore, I examined whether NgR1 and RhoA are involved in 
MAG-mediated microglial process inhibition. Microglia were isolated from NgR1-
deficient mice and plated on control or MAG-expressing CHO feeder layers for 24 hrs. 
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Interestingly, microglial cells cultured on MAG-CHO cells had a less processed 




























Figure 11. MAG-mediated microglial process inhibition is partially NgR1-dependent 
A) Microglia isolated from NgR1-deficient P0-P2 mixed glial cultures were cultured on confluent 
monolayers of control or MAG-expressing CHO cells. The co-cultures were fixed after 24 hrs and stained 
for Mac-1. Microglia had a ramified and often bipolar morphology when cultured on control-CHO cells, 
while they become more round and less processed when cultured on MAG-CHO cells. Scale bars, 10 μm. 
B) The microglial morphology was determined by the ramification index (RI). NgR1-deficient microglia 
had a significantly higher RI on MAG-CHO cells (0.33±0.008) than on control-CHO cells (0.26±0.006). 
All results represent the mean RI±SEM for 300-350 microglial cells from at least three independent 
experiments. A Student’s t-test was applied (***P<0.0001).  
 
The quantification of the microglial ramification index (RI) revealed that NgR1-deficient 
microglia on MAG-CHO cells were significantly more ramified (0.33±0.008) compared 
to microglia on control-CHO cells (0.26±0.006) (Fig.11B), but this was significantly 
reduced compared to the ramification index of wild-type microglia plated on MAG-CHO 
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cells (0.39±0.009) (Fig.10B). These results suggest that MAG-elicited inhibition is 






























































Figure 12. MAG-induced microglial inhibition involves the activation of RhoA 
A) Microglia isolated from wild type P0-P2 mixed glial cultures were cultured on confluent monolayers of 
control or MAG-expressing CHO cells, in the presence or absence of the Rho-associated kinase inhibitor, 
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Y27632 (20 μM). The co-cultures were fixed after 4 hrs and stained for Mac-1. Microglia had a ramified 
morphology when cultured on control-CHO cells, while they become more round and less processed when 
cultured on MAG-CHO cells. In the presence of the Rho kinase inhibitor, Y27632, the MAG-elicited 
microglial process inhibition was blocked and the cells had a more processed morphology. Scale bars, 10 
μm. 
B) The microglial morphology was determined by the ramification index (RI=4π (cell area/cell 
perimeter2)). This quantification revealed that microglial cells had significantly smaller RI on control-CHO 
cells (0.26±0.007) than on MAG-CHO cells (0.32±0.008). Additionally, this inhibition was blocked in the 
presence of the Y27632 inhibitor, as there was no significant difference between the RI of microglial cells 
cultured on MAG or control- CHO cells (0.20±0.007 and 0.21±0.006 respectively). All results represent the 
mean RI ±SEM for 300-350 microglial cells from at least three independent experiments. A Student’s t-test 
was applied (***P<0.0001).  
C) The supernatants of the microglial-CHO co-cultures in the absence (-) or presence (+) of the Rho-
associated kinase inhibitor Y27632, were analyzed with ELISA for chemokine and cytokine release and 
compared with microglial cells plated on poly-L-lysine (PLL). There was no release of TNF-α and low 
release of MIP-1α excluding the possibility of microglial activation in these culturing conditions. The data 




To assess whether the downstream cascade from all receptors involved leads to RhoA 
activation, the microglial/CHO co-cultures were incubated with Y27632, a Rho-
associated kinase (ROCK) inhibitor. Microglial cells isolated from wild-type mice were 
plated on confluent monolayers of MAG-CHO or control-CHO cells for 4 hrs. Under 
control conditions, even for as short a period as 4 hrs, microglia displayed an elongated 
and processed morphology (Fig.12A). Notably, microglial process outgrowth was 
strongly inhibited on MAG-CHO cells and microglia showed an amoeboid morphology. 
In the presence of the ROCK inhibitor, MAG-elicited microglial inhibition was fully 
reversed (Fig.12A). The quantification of the ramification index (RI) revealed that 
microglia plated on MAG-CHO cells had a significantly increased mean RI (0.32±0.008) 
compared to control-CHO co-cultures (0.26±0.007), indicating a less processed 
morphology. Interestingly, MAG-mediated microglial process inhibition was reversed in 
the presence of the Rho-associated kinase inhibitor Y27632 and was not significantly 
different from the control condition (change from 0.21±0.006 in the control-CHO to 
0.20±0.007 in the presence of MAG) (Fig.12B). To exclude any microglial effects of the 
CHO cells in the presence or absence of the ROCK inhibitor, the supernatants of the co-
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cultures were tested for cytokine and chemokine release. The ELISA analysis of the 
supernatants showed no signs of microglial activation compared to microglia plated on 
PLL (Fig.12C). Taken together, these data suggest that the downstream signalling 
cascade that leads to microglial process inhibition after encountering MAG involves the 
activation of the Rho-associated kinase. 
 
4.1.4 Microglia avoid myelin-associated glycoprotein as a substrate in a stripe assay 
As an independent approach, a substrate stripe assay was employed to assess the 
repulsive influence of MAG on microglia in more detail and without the influence of 
other molecules expressed at the surface of CHO cells. Recombinant proteins containing 
only the extracellular domain of MAG (full length Ig domains 1-5 or “truncated” 
containing only the Ig domains 1-3) were purified from CHO cells (Fig.13). The fully 
glycosylated protein (MAG d1-5) was purified from wild-type CHO cells and the 
proteins lacking N-glycans were purified in mutant CHO cells (MAG d1-5L and 
MAGd1-3L). These proteins were further used as soluble proteins or as a substrate for 









































































Figure 13. Recombinant MAG proteins 
The full length of the extracellular domain of MAG d 1-5, as well as a mutant form comprising the Ig-like 
domains 1-3, was purified in CHO cells. CHO cells stably expressing wild type MAG were used to purify 
fully glycosylated recombinant proteins (MAG d1-5, ∼80kDa), while CHO cells lacking glycosylation 
enzymes and stably expressing mutant MAG were used for purification of proteins lacking N-glycans and 




In the stripe assay, the entire coverslip was pre-coated with poly-L-Lysine (PLL) and 
additional stripes of MAG were used to test its inhibitory activity. This assay could 
reflect the in vivo situation where microglial processes can grow near to or avoid MAG. 
The microglial processes displayed a clear preference for the PLL-lanes, avoiding the 
MAG-coated lanes (Fig.14A). Interestingly, microglia aligned their processes near the 
MAG stripes without crossing, suggesting that MAG is not permissive but rather gives a 
direction to microglial process outgrowth. As previously shown in neurons, MAG-
elicited neurite outgrowth inhibition does not depend on the sialic acid binding and the 
inhibitory site on MAG is localized within the Ig domain 5 (Tang et al., 1997; Cao et al., 
2007). In order to assess which MAG domains are responsible for microglial inhibition, a 
shortened form of MAG lacking the domains 4 and 5 (MAG d1-3) was employed 
(Fig.14B). This recombinant protein was expressed in a mutant CHO cell line and 
therefore lacked any N-linked carbohydrates and sialic acid. Interestingly, the microglial 
cells were repelled by MAG, even in the absence of N-glycosylation and sialic acid and 
the absence of the Ig domains 4/5. In order to confirm the role of NgR1 in MAG-
mediated microglial process inhibition, the same assay was repeated with NgR1-deficient 
microglial cells (Fig.14C). Quantification of the microglial cells growing or avoiding the 
MAG stripes revealed that the full length MAG (MAG d1-5) was not permissive for 
wild-type microglial process outgrowth (86.2±2.5% of total cells on PLL), while a small 
number of microglial cells grew completely or partially on MAG stripes (13.8±2.5% of 
total cells) (Fig.14E). The absence of N-glycosylation and the Ig domains 4/5 did not lead 
to an increase of microglial growth on the MAG lanes (88.3±2.2% of total cells on PLL 
and 11.8±2.2% on MAG). Quantification of the NgR1-deficient microglial cells growing 
in or crossing the MAG d1-5 stripes revealed a significant increase in the number of cells 
compared to wild-type microglia (35±0.9% of total cells and 13.8±2.5% respectively), 
but there was significantly more avoidance of the MAG stripes compared to PLL 
(35±0.9% of total cells on MAG compared to 65±0.9% on PLL) (Fig.14E). To make sure 
that these differences were not due to technical handling, FITC-conjugated streptavidin 
was used as a control (Fig.14D). Indeed, 69.8±3.4% of the total number cells grow 
(19.5±2.7%) or cross (50.3±1%) the streptavidin stripes. Taken together, these results 
confirm the MAG-elicited microglial process inhibition and show that this is dependent 

































































Figure 14. MAG is an inhibitory substrate for microglial cells 
Coverslips were precoated with poly-L-Lysine (PLL). Full-length MAG (d1-5) (A,C), mutant MAG (d1-3) 
(B) or FITC-conjugated streptavidin (D) was added in a stripe pattern. Wild-type (A,B,D) and NgR1-
deficient (C) microglial cells were plated for 24 hrs and coverslips were fixed and stained for Mac-1 and 
MAG.  
A-D) Microglial cells were plated on alternating stripes of PLL/MAG d1-5 (+) or PLL (-) stripes. Note that 
microglial processes aligned themselves along the MAG stripes but avoid crossing them (A). In the absence 
of the MAG Ig-like domains 4 and 5, microglial cells avoided the MAG stripes and preferred the PLL lanes 
(B). The majority of NgR1-deficient microglia avoided MAG d1-5 lanes, but there was an increased 
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number of microglia growing on or crossing the MAG stripes (C). As a control for the microglial growth 
behaviour in a stripe pattern of substrates, FITC-conjugated streptavidin was applied. Microglia were not 
inhibited by streptavidin (D). Scale bars, 20 µm. 
E) The quantification of microglial process outgrowth on the different substrates reveals that there was a 
significantly lower number of microglia growing on or crossing MAG stripes (13.8±2.5%) compared to 
PLL (86.2±2.5%) and this repellence depended on the Ig domains 1-3 (88.3±2.2% on PLL). Additionally, 
the absence of NgR1 led to a partial improvement of the MAG inhibition, but was still significantly 
different from the PLL stripes (65±0.9% of total cells on PLL and 35±0.9% growing or crossing MAG 
stripes). In the control, streptavidin allowed the outgrowth of microglial processes.  The results represent 
the mean percentage of the total cell number ± SEM for more than 200 microglial cells per experiment and 
at least four independent experiments. Student’s t-test was applied (***P<0.0001, **P=0.0012).  
 
4.1.5 Soluble myelin-associated glycoprotein induces microglial inflammatory 
response. 
MAG does not only exist as a transmembrane protein, but also as a soluble MAG 
fragment solely consisting of the extracellular domain, termed dMAG, previously 
identified in the CSF of normal humans and patients with demyelinating diseases 
(Yanagisawa et al., 1985). It was additionally shown in vitro that soluble MAG fragments 
can be released during myelin preparation and that this retains its neurite inhibitory 
properties (Tang et al., 1997). Therefore, the microglial response to soluble dMAG was 
further assessed. Primary microglial cells were treated with different concentrations of 
the soluble full-length MAG d1-5 (Fig.15A,D,G,J), the non N-glycosylated full length 
MAG d1-5L (Fig.15B,E,H,K), or the mutant form of MAG d1-3L (Fig.15C,F,I,L). The 
secretion of cytokines and chemokines, such as interleukin-6 (IL-6), tumor necrosis 
factor (TNF-α), KC (murine equivalent of growth regulatory oncogene-α (GROα)) and 
macrophage inflammatory protein-1α (MIP-1α), was assessed in the supernatants after 20 
hrs. Surprisingly, the incubation of primary microglia with soluble dMAG resulted in a 
dose-dependent release of different cytokines and chemokines. Untreated cultures were 
devoid of any measurable cytokine or chemokine release (data not shown) and 
lipopolysaccharide (LPS) (1ng/ml) stimulation was used as a reference for known 
microglial responses. The MAG-elicited cytokine and chemokine release was normalized 
to the LPS-induced release and presented as a percentage. Interestingly, the microglia 
showed a maximum response after 1 μg/ml dMAG exposure and this release was not 
dependent on the glycosylation, sialic-acid binding or the Ig domains 4/5 of MAG. These 
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results suggest that soluble dMAG has a novel role, namely that of inducing a strong 
microglial inflammatory response when presented in high concentrations and this effect 
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Figure 15. Effects of soluble dMAG in primary microglial cytokine and chemokine release 
Primary microglial cells were plated for 24 hrs and then incubated with different concentrations of 
recombinant glycosylated full-length MAG d1-5 (A,D,G,J), non- glycosylated full-length MAG d1-5L 
(B,E,H,K), or mutant MAG d1-3L (C,F,I,L). After 20 hrs, the supernatants were collected and tested for 
 66
RESULTS 
cytokines and chemokines. Lipopolysaccharide (LPS)-induced microglial stimulation was used as an 
internal control. There was a dose-dependent response of microglia to different concentrations of soluble 
dMAG. The microglial response to soluble MAG did not depend on N-glycosylation or the Ig-like domains 
1-3 and it occurred in a dose-dependent manner. The data is normalized to control (LPS) and expressed as 













































































































































































Figure 16. Blocking the Fcγ receptors does not alter the microglial inflammatory response to soluble 
MAG  
Primary microglial cells were plated for 24 hrs and then incubated shortly with different concentrations of 
Fcγ receptor blocking antibodies before plating in the presence of 1 μg/ml of recombinant MAG and 
different concentrations of the blocking antibodies. The supernatants were collected after 20 hrs and 
analyzed for cytokine and chemokine release. Blocking the Fcγ receptors II and III (CD32/CD16) did not 
alter the inflammatory response of microglia in the presence of the soluble MAG proteins (A,B). 
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Additionally, blocking the Fcγ receptor I (CD64) in the presence of the soluble MAG proteins did not 




The recombinant MAG proteins were purified as Fc-chimeras and then the Fc-tag was 
removed by enzymatic digestion with a 3C protease. To test whether any Fc-portion was 
uncleaved or co-purified with these proteins, western blot analysis was performed using 
an antibody directed against the Fc and did not reveal any traces of Fc (data not shown). 
In order to exclude any possibility that there might be low, uneasily detectable amounts 
of Fc as impurities that could trigger the microglial inflammatory response, all three Fcγ 
receptors were blocked by incubating with the specific antibodies (Fig.16).  
 
In vivo, microglial cells express at least three Fc receptors, namely FcγRI (CD64), II 
(CD32) and III (CD16), and these receptors mediate phagocytosis and cytotoxicity in 
vitro (Ulvestad et al., 1994). The microglia exhibited the maximum inflammatory release 
when 1 μg/ml of recombinant MAG proteins was used (Fig.15). Therefore, this amount 
(1 μg/ml) and different concentrations of the blocking antibodies were used to test 
whether the inflammatory response would be altered. Blocking the FcγRII and FcγRIII 
did not lead to any change in the MAG-mediated microglial inflammatory response 
(Fig.16A,B). Additionally, blocking the FcγRI did not change the MAG-induced 
microglial inflammatory response (Fig.16C,D). These results show that there is no 
interference from any Fc-portions possibly co-purified with the recombinant MAG in the 
soluble MAG-elicited microglial inflammatory response and that the Fc receptors are not 
involved in the MAG-microglial signalling. 
 
4.1.6 Surface-presented MAG-mediated microglial response does not interfere with 
the TLR pathways 
Twelve mouse toll-like receptors (TLRs) have been identified that are important for the 
front-line defence against pathogens, even in the brain (Hanisch et al., 2008). Recent 
studies have shown that these receptors might not only signal in the presence of 
pathogens, but also due to endogenous signals that indicate threats to the brain’s 
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structural and functional integrity (Larsen et al., 2007). Consequently, I set about testing 
whether the function of surface-presented MAG is not only restricted to microglial 
process outgrowth, but might interfere with other pathways by providing anti-
inflammatory signals. To test whether the MAG-elicited microglial signalling interferes 
with the TLR pathways, known TLR agonists for the toll-like receptors 1, 2, 4 and 6 were 
used. Microglia were cultured on control and MAG-CHO layers and stimulated with 
Pam3SK4 (a TLR 1/2 agonist), LPS (a TLR4 agonist) and MALP-2 (a TLR 2/6 agonist) 
(Fig.17). In the absence of TLR agonists, there was no microglial inflammatory response, 
as measured for TNF-α (Fig.17A), KC (Fig.17B), MIP-1α (Fig.17C) and IL-6 (data not 
shown). Surprisingly, the addition of Pam3SK4 and LPS did not stimulate an 
inflammatory response in the microglia (Fig.17), suggesting that other molecules 
expressed on the surface of the CHO cells might suppress this activity. On the other hand, 
MALP-2 led to a low KC release and increased MIP-1α release but without any 
difference between the control and MAG-CHO/microglia co-cultures. These data suggest 
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Figure 17. Surface presented MAG does not involve common pathways with the toll-like receptors 
(TLRs) in microglia 
Primary microglial cells were plated for 24 hrs on confluent monolayers of control and MAG-expressing 
CHO cells in the absence or presence of the toll-like receptors (TLRs) agonists Pam3SK4 (TLR 1/2), LPS 
(TLR 4) and MALP-2 (TLR 2/6). The analysis for TNF-α (A), KC (B) and MIP-1α (C) release revealed a 
general suppressive effect of other surface-expressed molecules on CHO cells for the Pam3SK4 and LPS 
stimulation. In case of the MALP-2 stimulation, there was no difference in the microglial response in the 
presence of the agonist and in the presence or absence of MAG. The data is expressed as mean ± SEM 
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Figure 18. MAG-elicited microglial response does not involve common pathways with the toll-like 
receptors (TLRs)  
Primary microglial cells were plated for 24 hrs on poly-L-lysine (PLL) and MAG or only PLL-coated 
coverslips in the absence or presence of the toll-like receptors (TLRs) agonists Pam3SK4 (TLR 1/2), LPS 
(TLR 4) and MALP-2 (TLR 2/6). The analysis for TNF-α (A), MIP-1α (B) and IL-6 (C) release showed a 
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distinct microglial response in the presence of the TLR agonists independent of the presence of MAG. The 
data is expressed as mean ± SEM (n ≥ 6, at least three independent experiments). 
 
To better assess the involvement of the TLR 1, 2, 4 and 6 pathways by using TLR agonist 
stimulation, such as Pam3SK4, LPS and MALP-2, without the influence of the CHO 
cells, the recombinant MAG protein (MAG d1-5) was employed. Coverslips coated with 
PLL and MAG or PLL only were used as substrates for microglia in the presence of the 
TLR agonists (Fig.18). Surprisingly, there was an inflammatory response when the 
microglia were cultured on MAG, even in the absence of any TLR agonist, probably due 
to an amount of unbound soluble protein that can elicit such an effect. Taking this into 
account, I analyzed whether the addition of the TLR agonists would have an additive 
effect on the chemokine and cytokine release. The results of this study show that the 
MAG-microglial interaction probably does not involve common receptors or downstream 
signalling with the toll-like receptor 1, 2, 4 and 6-related pathways. 
 
4.1.7 In vivo imaging of the microglial behaviour reveals changes in the absence of 
MAG 
To further investigate whether MAG acts as an inhibitor of microglia in vivo, two-photon 
laser scanning microscopy was employed in the dorsal column of the spinal cord of 
anaesthetized mice. To study microglial behaviour in the living mice, wild-type and 
MAG-deficient mice were crossed with transgenic mice in which microglia express the 
enhanced green fluorescent protein (EGFP) and neurons express the enhanced yellow 
fluorescent protein (EYFP) (Jung et al., 2000; Winter et al., 2007). Microglia, as 
previously shown (Davalos et al., 2005), had very motile processes in the normal brain 
and this movement was adjusted in the case of ‘danger signals’. Based on the working 
hypothesis MAG acts as an inhibitor of microglial process outgrowth, so the overall 
microglial process outgrowth should be altered in the absence of MAG. This change 
would not be due to microglial activation, as it was previously shown that the absence of 























Figure 19. Altered microglial morphology in the absence of MAG in the spinal cord of anaesthetized 
mice 
In vivo imaging of GFP-positive microglial cells and YFP-positive axons in the spinal cord of wild type (A, 
C, E) or MAG-deficient mice (B, D, F) revealed differences in the microglial morphology. 
A, C, E. Microglial cells had small somata and a large number of thin and extremely ramified processes 
that extend along the myelinated axons in a distinct spatial pattern (arrows). 
B, D, F. Microglia changed their morphology in the absence of MAG. There was a loss of microglial 
process ramification and the microglia somata were in closer proximity. It is notable that an increased 
number of microglial processes associates with the neighbouring axons (dashed arrow). Scale bars, 20 µm. 
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Indeed, there was a striking difference in the overall pattern of microglial process 
distribution in the absence of MAG. In contrast, the microglial somata and main branches 
remained morphologically stable over the period of observation independently of the 
presence or absence of MAG, and there was no obvious difference in the overall 
microglial process movement (data not shown). In the wild-type mice, thin and ramified 
microglial processes were extended along the myelinated axons (arrows) displaying a 
distinct cell-to-cell territorial distribution (Fig. 19A, C, E). Strikingly, in the absence of 
MAG, microglial processes lost this distribution pattern and they were apposed to 
neurons (dashed arrow) in an increased density (Fig. 19B, D, F). This data suggests that 
in vivo surface-presented MAG and/or low amounts of soluble MAG that is possibly shed 
from the membrane act as an inhibitor of microglial process outgrowth, which also 
determines their distribution. 
 
4.1.8 Activation of microglial cells leads to myelin ‘attack’ in the absence of MAG 
Next, an in vivo model where microglia are activated was used to investigate whether 
MAG-mediated microglial process inhibition has a physiological role in a disease 
situation. In adult PLP-deficient mice, an increased number of axonal swellings is present 
and accompanied by microglial activation (Griffiths et al., 1998). In a previous study, 
young MAG-deficient mice showed no signs of microglial activation as revealed by Mac-
3 staining, a marker of microglial activation (Loers et al., 2004). In the same study, the 
number of Mac-3-positive activated microglia was significantly higher in aged MAG-
deficient mice than in the wild-type controls. Therefore, PLP-deficient mice were crossed 
with MAG-deficient mice to yield double mutants and to assess the role of MAG with 
respect to microglial behavior in a disease model. In a previous study, the early onset of 
axonal degeneration in MAG*PLP double mutants was reported (Uschkureit et al., 2000). 
In order to assess the microglial status in this double-deficient mouse model (‘resting’ 
versus ‘activated’ microglia) paraffin-embedded tissue was stained with Mac-3 (Fig.20). 
In the current study, low microglial activation was observed in the single PLP- (b) or 
MAG-deficient mice (c), and strong Mac-3 immunoreactivity in MAG*PLP double 
mutants (a). Interestingly, the microglial activation observed in the double mutants was 









Figure 20. Increased microglial activation in the MAG*PLP double mutant mice 
Paraffin-embedded tissue from MAG*PLP double-deficient (a), PLP -deficient (b) and MAG-deficient 
mutant mice (c) at the age of 13 months was immunostained for Mac-3 and examined by light microscopy. 
There was an increased immunoreactivity in the dorsal column of the spinal cord of the MAG*PLP double 
mutants (a) (arrow), while there were only a few Mac-3 positive cells in any of the single mutants (b,c). 
Scale bars, 25 µm.  
 
 
To further assess the interaction of the myelin sheath with microglia, the mice were 
processed for electron microscopy. An earlier study of MAG*PLP double mutants in our 
lab (unpublished data) revealed the presence of microglial cells invading the periaxonal 
space although there was no prior report of such a case in any of the single mutants or 
other myelin protein mutants. Additionally, these mice had a short life span of 6 months. 
In the current study, the mice lived >12 months. For the present analysis, PLP-deficient 
mice heterozygous for the mag allele were used; it was previously suggested that there 
are no differences between mag+/- and mag-/- mice with respect to myelin abnormalities 
(Fujita et al., 1998). Interestingly, an increased number of large lipid-laden 
microglia/macrophages was observed in semithin sections of the MAG*PLP double 
mutants (Fig.21Aa) but in neither of the single mutants (Fig. 21Ab,c) at the age of 13 
months. As previously described (Griffiths et al., 1998), demyelination and an increase in 
the number of microglial nuclei (Fig. 21Ab), a sign of microgliosis, were observed in 
PLP-deficient mice. The MAG-deficient mice did not show any increase in the number of 
microglial nuclei in the semithin level and the myelin sheath was intact (Fig.21Ac). In 
order to confirm these results with another method, paraffin-embedded tissue was used 
and processed with May-Giemsa staining (Fig.21B). As expected, there were cells with a 
light blue irregular foamy cytoplasm, much vacuolated in MAG*PLP double mutant mice 
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(a), but not in the PLP or MAG single deficient mice (b and c respectively). Taken 
together, these results show that due to PLP-deficiency activated microglia attack and 
ingest enormous amounts of myelin in the absence of MAG. This finding suggests that 
MAG acts as an inhibitor in the myelin sheath against activated microglia, supporting the 
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Figure 21. Activated microglia attack the myelin sheath in the absence of MAG in vivo 
A) Semithin cross sections from the dorsal column of the spinal cord of MAG*PLP double-deficient (a), 
PLP-deficient (b) and MAG-deficient (c) mutant mice were examined by light microscopy. These animals 
were at the age of 13 months. The presence of foamy macrophages/microglia attacking the myelin sheath 
(white lipid droplets) (arrows) were only present in the MAG*PLP double mutants (a) and not in any of the 
single mutants (b,c). The absence of PLP caused microglial activation, seen at this level as an increase in 
the microglial nuclei (b). The integrity of myelin and the presence of microglia cells were normal in the 
MAG-deficient mice (c). Scale bars, 5 µm.  
B) Paraffin-embedded tissue from MAG*PLP double-deficient mutants (a) and the respective PLP (b) and 
MAG (c) single-deficient mutants was stained with May-Giemsa. Cells with light blue vacuolated 
cytoplasm (arrows) were only present in the double mutants (a) and not in the PLP or MAG single deficient 




4.1.9 The role of MAG in LPS treated mice 
Microglial cells are key components of the brain’s defence mechanism in various 
pathologies, such as injury, autoimmune and neurodegenerative diseases and infections 
(Kreutzberg, 1996). Therefore, I wanted to assess whether the MAG-mediated signalling 
to microglia plays a role in pathology in a different model to the one described above 
using myelin mutant mice. A model that can mimic systemic inflammation in mice is the 
administration of lipopolysaccharide (LPS), a component of the Gram-negative bacterial 
cell wall (Andersson et al., 1992; Hauss-Wegrzyniak et al., 1998). Although it has long 
been believed that the brain is an immune-privileged organ, it was shown that even the 
intraperitoneal injection of LPS could lead to microglial activation in the brain (Kloss et 
al., 2001). Therefore, 2-3-month-old wild-type and MAG-deficient mice were injected 
intraperitoneally with 15 mg LPS/kg of body weight and sacrificed at various time points 
(Fig.22). To investigate the effect on microglia, the tissue was embedded in paraffin and 
the cerebellum was analyzed with Mac-3 immunoreactivity. At this age, the non-injected 
wild type and MAG-deficient mice exhibited very few, almost undetectable numbers of 
Mac-3-positive cells (Fig.22A,B). After LPS stimulation and after only 12 hrs, the 
number of Mac-3-positive cells increased with a more prominent population in the MAG-
deficient mice (Fig.22C,D). The next 12 hrs of LPS stimulation, did not lead to additional 
microglial activation in the MAG mutant mice (Fig.22F), but there was an increase in the 
wild-type mice (Fig.22E). The peak of microglial activation and the maximum difference 
between the genotypes was reached after 48 hrs (Fig.22G,H). After a further 48 hrs, there 
was a small decrease in the population of Mac-3 positive cells in both genotypes 
(Fig.22I,J). Interestingly, a number of MAG-deficient mice died 72 hrs after LPS 
administration while wild-type mice did not show any signs of sickness. It is important to 
consider that intraperitoneal LPS administration not only affects the immune system of 
the brain, but also the peripheral immune system. Nevertheless, these results show a 
difference in the microglial response after LPS administration dependent on the genotype, 
which suggests that MAG might play a role in the myelin-microglial interaction even 


















Figure 22. Persistent microglial 
activation in LPS treated mice in 
the absence of MAG 
Light micrographs of the 
cerebellum of control (A,B), after 
12 hrs (C,D), 24 hrs (E,F), 48 hrs 
(G,H) and 96 hrs (I,J) of the 
lipopolysaccharide (LPS) 
intraperitoneal injection of wild-
type (A,C,E,G,I) and MAG-
deficient mice (B,D,F,H,J). 
Sections were immunostained with 
the Mac-3 antibody, a microglial 
activation marker. There was 
almost no immunoreactivity in the 
control wild-type (A) and MAG-
deficient mice at the age of 3-4 
months (B). LPS stimulation led to 
increased microglial activation in 
MAG-deficient compared to wild-
type mice at all different time 
points. Note that the peak of 
microglial activation was after 48 
hrs in the MAG-deficient mice 
(arrows), although there was 
already strong Mac-3 
immunoreactivity even at 12 hrs 








4.1.10 The role of MAG in EAE mice 
Multiple sclerosis (MS) is a widespread inflammatory disease of the central nervous 
system (CNS) that results in progressive demyelination and axonal loss (Bruck and 
Stadelmann, 2005; Trapp and Nave, 2008). Rodent models of experimental autoimmune 
encephalomyelitis (EAE) have been widely used to examine the mechanism of MS and 
the preclinical efficacy of mainly immunomodulatory drugs. The number of EAE models 
is large, each reflecting aspects of the subtypes of pathologies observed in the CNS of 
MS patients. One can achieve a range of pathological and temporal outcomes using a 
combination of different strains of mice, rats, or other mammals and different epitopes 
for immunization (peptides, whole proteins, or complex mixtures like spinal cord 
homogenate (Stromnes and Goverman, 2006).  
 
To further assess the potential role of the MAG-microglial interaction in a strong 
inflammatory disease, EAE-induced mice from a wild-type and MAG-deficient 
background were analyzed. First, the extent of demyelination and cellular infiltration was 
evaluated; therefore, the spinal cords were removed and embedded at different time 
points after immunization and stained for Luxol-fast blue and counterstained for ‘nuclear 
red’ (Fig.23). This staining allows the identification of demyelinating areas and the 
cellular infiltration from the periphery (T-cells and macrophages). Behavioural signs of 
EAE rarely started earlier than 10-12 days post-immunization (Stromnes and Goverman, 
2006). There was no obvious demyelination and cell infiltration in the dorsal column of 
the wild-type mice 1dpi (day post immunization), but there was a subtle infiltration in the 
MAG-deficient mice (Fig.23A,B). The demyelination and cellular infiltration proceeded 
without any obvious differences between the wild-type and MAG-deficient mice at 12 
and 30 days post-immunization, revealing a peak at 30 d.p.i (Fig.23C-F). The degree of 
demyelination and possibly remyelination was assessed at 5 months p.i, showing an 
intense LFB signal in the wild-type mice (Fig.23G), but a focal loss of the signal in 
disperse areas of the dorsal column in MAG-deficient mice (Fig.23H). Collectively, these 
results revealed a difference in the extent of demyelination and cellular infiltration 
between the two genotypes, suggesting the involvement of MAG in the onset and 






















































Figure 23. Histological analysis of CNS tissue from EAE wild-type and MAG-deficient mice 
Spinal cords from wild-type (A,C,E,G) and MAG-deficient (B,D,F,H) mice were isolated at 1d, 12d, 30d 
and 5m post-immunization and embedded in paraffin. Sections were analyzed for demyelination and cell 
infiltration using a combined Luxol-fast blue (LFB) with ‘nuclear red’ staining. There was an early onset of 
cellular infiltration in the MAG-deficient mice (arrow) (B) compared to control (A). The extent of 
demyelination and cellular infiltration between the different genotypes was indistinguishable at 12 d.p.i 
(C,D), when the behavioural sickness of the animals actually starts. The peak of the demyelination and 
cellular infiltration was similar for both wild-type and MAG-deficient mice at 30 d.p.i (arrows) (E,F). At 
later stages, such as 5 m.p.i, the extent of demyelination in the wild-type mice was no longer so obvious 
(G), while there are dispersed demyelinating areas in the MAG-deficient mice (H). Scale bars, 50 µm. 
 
To further examine the microglial/macrophage behaviour during the different stages of 
the disease and with regard to the two different genotypes, the paraffin sections were 
stained with Mac-3 (Fig.24). There was dispersed microglial activation in the dorsal 
column of MAG-deficient mice as early as 1 d.p.i (Fig.24B), but there was no obvious 
immunoreactivity in the wild-type animals (Fig.24A) at the same time point. The 
microglial/macrophage activation proceeded at day 12 p.i. in the wild-type mice 
compared to MAG-deficient mice (Fig.24C,D) and remained persistent after 30 d.p.i. 
(Fig.24E,F). Contrary to the LFB results, there was persistent immunoreactivity in the 
wild-type mice (Fig.24G) after 5 months post-immunization, while no obvious Mac-3-
positive cells were evident in the MAG-deficient mice (Fig.24H). Taken together, these 
data suggest that MAG is involved in regulating the microglial/macrophage behavior 
















































Figure 24. Histopathology of CNS tissue from EAE wild-type and MAG-deficient mice 
Paraffin embedded spinal cords from wild-type (A,C,E,G) and MAG-deficient (B,D,F,H) mice at 1d, 12d, 
30d and 5m post-immunization were immunostained with Mac-3, a microglial/macrophage marker. There 
was an early onset of microglial activation and the presence of macrophages in the MAG-deficient mice 
(arrows) (B) compared to control (A). In the wild-type mice, the presence of microglia/macrophages peaks 
at 12 d.p.i (arrows) and was persistent after 30 days and 5 months post-immunization. In contrast, in MAG-
deficient mice the presence of microglial/macrophages in the dorsal column was reduced over time. Scale 
bars, 25 µm 
 
4.2 Astrocytes and myelin-associated inhibitors 
4.2.1 Astrocytes express the Nogo-66 receptors and co-receptors 
Astrocytes are also reactive glial cells with motile processes as shown in vivo (Hirrlinger 
et al., 2004). Therefore, the same myelin-associated inhibitory mechanism might also 
take place against the astrocytes. First, the astrocytic expression of the receptors and the 
co-receptors known to bind the myelin-associated inhibitors in neurons was assessed. 
Astrocytes were purified from postnatal transgenic mice that express the enhanced green 
fluorescent protein (EGFP) under the astrocytic glial fibrillary acidic protein (GFAP) 
promoter (Nolte et al., 2001) (Fig.25A). The FACS-isolated EGFP-positive astrocytes 
were analyzed by quantitative RT-PCR (Fig.25B) for the expression of the receptor 
complex that is known to mediate the myelin-mediated inhibition in neurons and based 
on our results in microglia. Indeed, at the mRNA level the isolated astrocytes expressed 
all three homologues of Nogo-66 receptor, namely NgR1, NgR2 and NgR3. Additionally, 
astrocytes expressed the co-receptors Lingo-1, EGFR and the low-affinity neurotrophin 
receptor p75. They additionally expressed the Troy and EGF receptor in relatively high 
amounts when compared to beta-actin. The expression of GFAP was used as an astrocytic 
control. These results show for the first time that isolated astrocytes express the receptors 
and co-receptors known to bind the myelin-associated inhibitors and support previous 



















































































Figure 25. Astrocytic expression of the Nogo-
66 receptors (NgRs) and co-receptors 
A) Newborn heterozygous transgenic GFAP-
EGFP mice were employed to isolate highly pure 
brain astrocytes. The EGFP-positive astrocytes 
could be distinguished clearly and isolated 
(window P6) from the total brain cellular 
population. 
B) RNA from the FACS sorted astrocytes was 
isolated and processed for quantitative RT-PCR 
expression profile analysis. Beta-actin was used 
as a standard. Astrocytes expressed the NgR1 
and the two homologues NgR2 and NgR3 and 
the co-receptors Lingo-1 and p75. Additionally, 
the relative expression of Troy and EGFR was 
high. The glial fibrillary acidic protein (GFAP) 
expression served as an astrocytic marker. Data 






4.2.2 Astrocytic processes are inhibited by MAG 
The next question addressed was whether the myelin-associated inhibitors have an effect 
on astrocytes. Therefore, the same co-culture CHO or 3T3/astrocyte assay (Fig.9) was 
employed. Astrocytes were isolated from wild-type mixed glial cultures after shaking off 
the microglia and an additional mild trypsinisation step. These were plated for 24 hrs on 
confluent monolayers of control and MAG-expressing CHO and Nogo-A-expressing 3T3 
cells. Interestingly, astrocytes on top of control-CHO cells often had a bipolar and 
elongated morphology, while the length of their processes was decreased and there was 
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an increase in the number of ‘flattened’ astrocytes when cultured on the MAG-CHO 
monolayer (Fig.26). On the other hand, astrocytes had a bipolar and often multipolar 
morphology when cultured onto the Nogo-A-expressing 3T3 cell layer, indicating that 
Nogo-A does not inhibit the astrocytic processes. Interestingly, astrocytes were more 
multipolar on top of the 3T3 cells compared to the control-CHO cells, suggesting that 
other molecules expressed at the surface of these cell lines might influence the astrocytic 
morphology. Taken together, these preliminary data show that, in vitro, MAG but not 





Figure 26. Astrocytes are inhibited by myelin-associated glycoprotein 
Astrocytes isolated from wild type P0-P2 mixed glial cultures after shaking off the microglia were cultured 
on confluent monolayers of control or MAG-expressing CHO cells and Nogo-A-expressing 3T3 cells. The 
co-cultures were fixed after 24 hrs and stained for the glial fibrillary acidic protein (GFAP) using a species-
specific polyclonal antibody. Astrocytes had an elongated morphology when cultured on control-CHO 
cells, while their processes became shorter when cultured on MAG-CHO cells. The astrocytic processes 
were elongated in the presence of Nogo-A-expressing 3T3 cells. Scale bars, 20 μm. 
 
4.2.3 Astrogliosis in EAE mice 
In the diseased central nervous system, microglial activation is accompanied by 
astrogliosis. Major reactive changes of astrocytes in vivo include among others the up-
regulation of the glial fibrillary acidic protein (GFAP) accompanied by cellular 
hypertrophy. Astrocytes respond to “danger” signals in the CNS as well as the microglial 
cells. An example of such a response is multiple sclerosis, where astrocytes become 


















Figure 27. Astrogliosis in 
EAE mice 
Light micrographs of spinal 
cords from wild-type 
(A,C,E,G) and MAG-
deficient (B,D,F,H) mice 1d, 
12d, 30d or 5m post-
immunization. Sections 
were immunostained with 
the GFAP antibody, an 
astrocytic marker (arrows). 
There is no difference in the 
extent of the astrogliosis 
between the wild-type and 
MAG-deficient mice at any 
of the time points examined. 



















Therefore, I asked whether the MAG-mediated signalling to astrocytes plays a role in 
vivo under a pathological condition. Hence, the rodent EAE model was employed to 
assess the astrocytic response in wild-type versus MAG-deficient mice. The mice were 
sacrificed at different time points and the activation of astrocytes was evaluated as the 
immunoreactivity of GFAP (Fig.27). There was a strong astroglial response even after 1 
day post immunization (d.p.i.), but no difference between the two genotypes (Fig.27A,B). 
The same observations were made by comparing the extent of astrogliosis in the different 
genetic backgrounds at 12 d.p.i, 30 d.p.i and 5 months after immunization (Fig.27C-H). 
Collectively, these results show that the inhibitory role of MAG in the astrocytic process 
outgrowth found in vitro cannot be directly translated into the regulation of the astrocytic 
response in a strong inflammatory condition, such as the EAE model. 
DISCUSSION 
5. Discussion 
In higher vertebrates, the central nervous system (CNS) is one of the tissues that has 
limited regeneration capability. One of the obstacles known to limit axonal regeneration 
is the myelin sheath (Berry, 1982). In the last decade, extensive research has been carried 
out in the field of axonal regeneration to identify the myelin-associated inhibitors and 
underlying molecular pathways involved (Filbin, 2003; Liu et al., 2006; Yiu and He, 
2006). These inhibitors, i.e. MAG, Nogo and OMgp, act through the same neuronal 
receptor complex, composed by Ngr1/Lingo-1/p75 or Troy, which leads to neurite 
outgrowth inhibition. Nevertheless, the physiological role of these inhibitory mechanisms 
under non-pathological conditions has been neglected. Based on the hypothesis of this 
study these inhibitors might be directed towards the resident glial cells of the CNS, such 
as microglia and astrocytes, as the emergence of reduced regenerative ability in higher 
vertebrates coincides with the increasing complexity of the innate immune system and the 
appearance of the adaptive immune system (Popovich and Longbrake, 2008). 
 
5.1 Microglia express the repertoire of receptors and co-receptors known to bind the 
myelin-associated inhibitors 
The involvement of the Nogo-66 receptors and the co-receptors in myelin-mediated 
neurite outgrowth inhibition has been shown both in vitro and in vivo (Xie and Zheng, 
2008). As a first step to approach the present working hypothesis, I tested whether 
microglia also express this receptor complex. FACS-highly purified microglia from 
CX3CR1-EGFP transgenic mouse brains (Fig.7a) (Jung et al., 2000) were used and tested 
for the expression of these receptors at the mRNA level. Indeed, in this study it was 
shown that microglia express NgR1, NgR2, NgR3, Lingo-1, Troy and EGFR, though not 
the p75 neurotrophin receptor (Fig.7B). Additionally, the expression of NgR1 could be 
also confirmed at the protein level (Fig.7C). These results are in agreement with previous 
studies showing the expression of some of these receptors in microglia at the histological 
level in human tissues (Satoh et al., 2005; 2007). Furthermore, it was recently shown that 
these receptors are expressed in the counterpart cells of microglia in the PNS, the 
macrophages (Fry et al., 2007). Taken together, microglia express the molecular 
machinery known to bind the myelin-associated inhibitors and transduce the inhibitory 
signal to neurons. 
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5.2 A novel role of MAG in inhibiting microglial process outgrowth 
The next logical step to test my hypothesis was to assess whether microglia respond to 
the presence of the myelin inhibitors. Interestingly, a recent study revealed that the 
inhibitory role of myelin through the NgR receptor complex is extended in non-neuronal 
cells, such as macrophages (Fry et al., 2007). Employing an “outgrowth assay” 
previously described for neurons (Mukhopadhyay et al., 1994) with some modifications, 
microglia were co-cultured with CHO cells in the presence or absence of MAG. Here, 
microglial process outgrowth was inhibited by surface-presented MAG in vitro 
(Fig.10A,B). Microglial cells had fewer and shorter processes when cultured on MAG-
CHO feeder cells compared to control-CHO cells, and this change was independent of 
microglial activation (Fig.10C). However, to confirm the influence of MAG on 
microglial morphology, a stripe pattern of recombinant MAG was used as a substrate for 
microglia (Fig.14). In this assay, the inhibitory properties of MAG on microglial process 
outgrowth were reconfirmed as microglial cells avoided crossing the MAG-lanes. These 
data are the first to show that the inhibitory effect of MAG is not merely restricted to 
axons, but also targets the microglial cells in the CNS. On the other hand, Nogo-A-
expressing 3T3 fibroblasts did not lead to microglial process inhibition (Fig.10A), 
suggesting that Nogo-A is not inhibitory for microglia. It cannot be formally excluded, 
however, that this preliminary observation might be due to other molecules expressed at 
the cell surface of the 3T3 cells, which might promote process outgrowth and thus 
suppress the inhibitory properties of Nogo-A. Therefore, further experiments with Nogo-
A-knock down 3T3 cells are needed to elucidate the effect of Nogo-A on microglial 
morphology. Finally, it would be interesting to test whether microglial processes are 
specifically inhibited by MAG or they also respond to oligodendrocyte-myelin 
glycoprotein (OMgp). 
 
It is known that MAG not only binds to NgR1, but also NgR2 and gangliosides (Mehta et 
al., 2007). The binding of MAG to the neuronal NgR1 receptor complex or gangliosides 
leads to RhoA and downstream molecules such as Rho kinase (ROCK) activation and 
subsequently growth cone collapse (Vinson et al., 2001; Fournier et al., 2003; Mahta et 
al., 2007). Furthermore, microglia express the Nogo-66 receptors, as well as the co-
receptors Troy and Lingo-1 (Fig.7). I therefore tested whether MAG-mediated microglial 
inhibition is NgR1- and RhoA-dependent. Using NgR1-deficient mice and the Rho-
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asociated kinase inhibitor Y27632, I found that the MAG-mediated microglial process 
inhibition is only partly NgR1-dependent (Fig.11) but could be completely reversed by 
blocking the ROCK in the CHO/microglial co-cultures (Fig.12). The partial involvement 
of NgR1 in the MAG-elicited microglial avoidance was additionally verified in the stripe 
assay (Fig.14). These results suggest that microglial receptors of the myelin-associated 
inhibitors probably involve more than the NgR1, but all of the receptor signalling 
converts to RhoA activation. Additional to NgR2, which could not be experimentally 
tested as null-mutant mice have not been available for this study, novel receptors must be 
taken into account. Interestingly, the novel axonal receptor PirB (Atwal et al., 2008), 
which is unrelated to NgRs, has been very recently described to play an important role in 
myelin-associated inhibition. Its presence in glial cells at present is only speculative.  
 
Focusing on the inhibitory properties related to the molecular structure of MAG, this 
glycoprotein contains five extracellular immunoglobulin (Ig)-like domains with eight 
glycosylation sites and additional sialic acid charge in Ig domain 1 (Quarles, 2007). 
Furthermore, it was previously shown that MAG binds to neurons in a sialic acid-
dependent mechanism, but this is distinct from the inhibitory domain of MAG that 
resides within the Ig domain 5 (Kelm et al., 1994; Cao et al., 2007). Therefore, the 
domain specificity of MAG-elicited microglial inhibition was investigated by employing 
a truncated recombinant MAG (MAG Ig domain 1-3) in the stripe assay (Fig.14B). Here, 
it was shown that the domain of MAG inhibiting the microglial process outgrowth is 
located within the Ig domains 1-3. Additionally, it was shown that the N-glycosylation 
and the sialic acid charge of MAG do not play a role in the microglial inhibition. These 
results show that the inhibitory domain of MAG is different regarding the cell type that is 
targeted, namely neurons or microglia, suggesting that different recognition mechanisms 
might be involved in the two cell types. This is not surprising, as MAG is a member of 
the siglec protein family that are known to mediate cis- and trans-interactions with other 
members of the same family and are mainly expressed in immune cells (Crocker et al., 
2007). Therefore, MAG might interact with other siglecs residing at the microglial 
membrane. Further analysis regarding of other siglec members would shed some light on 
their potential involvement as binding partners of MAG. Taken together, microglial 
processes are repelled by MAG in vitro and this inhibition partly involves the NgR1 
receptor, while the downstream signalling leads to RhoA activation. Finally, the 
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important domains of MAG inhibiting the microglial process outgrowth are the Ig 
domains 1-3. 
 
5.3 MAG as a signal for microglial activation 
Apart from the MAG isoform as a type I transmembrane protein, a soluble proteolytic 
fragment of MAG, namely dMAG, was found in vivo (Sato et al., 1984; Yim and 
Quarles, 1992; Moller, 1996). This extracellular domain of MAG retained its neurite 
inhibitory properties (Tang et al., 1997). Moreover, it was shown that there was an 
increased amount of dMAG in patients with multiple sclerosis compared to healthy 
controls (Moller et al., 1987). In a recent in vitro study, it was shown that specific matrix 
metalloproteinases (MMPs), such as MMP-2, MMP-7 and MMP-9, mediate the cleavage 
of cell surface-presented MAG, as well as recombinant MAG-Fc chimera (Milward et al., 
2008). The expression of these metalloproteinases is upregulated in the MS (Yong et al., 
2007; Scarisbrick et al., 2008). I therefore hypothesized that, as a sign of myelin 
destruction, soluble dMAG might play a different role when presented to microglia. 
Consequently, the response of microglial cells was tested in the presence of soluble 
dMAG in different concentrations (Fig.15). These data revealed that the microglia 
responded to soluble dMAG in a dose-dependent manner by releasing cytokines and 
chemokines. Furthermore, as shown for the surface-presented MAG, this release was not 
dependent on the Ig domains 4/5. Interestingly, the cyto- and chemokine microglial 
release by MAG did not involve the Fc receptors, as demonstrated by blocking the 
receptors with specific antibodies (Fig.16). Finally, it would be interesting to investigate 
the effect of soluble MAG on microglia in vivo. For that reason, the soluble recombinant 
extracellular domain of MAG could be applied externally in the MAG-deficient mice and 
the microglial behaviour monitored using two-photon in vivo imaging. Taken together, 
microglia respond to the soluble extracellular domain of MAG in a dose-dependent 
manner and this inflammatory response is independent of N-glycosylation, sialic-acid 
moieties and the Ig domains 4/5.  
 
The present data suggest that MAG plays a dual role in microglial behaviour. When 
MAG is presented at the cell surface, it repels microglial processes while cleavage of 
MAG from the membrane, a sign of myelin destruction, leads to microglial activation 
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when presented in high amounts. Interestingly, in case of multiple sclerosis, the levels of 
MMPs are increased (Yong et al., 2007; Scarisbrick et al., 2008); this could lead to 
increased proteolytic cleavage and the release of dMAG, a pathological sign that could be 
“sensed” further by microglia and trigger their activation. Additionally, some of these 
MMPs are expressed by microglia and are upregulated in pathology, such as MS or LPS 
stimulation in vitro (Gottschall et al., 1995; Cossins et al., 1997). Therefore, it is 
conceivable that there is a feed back loop, where the increased shedding of MAG leads to 
microglial activation and the further upregulation of MMPs and subsequently an 
increased release of MAG. Consequently, one could think that the blocking of MMPs 
with some inhibitors could stop the activation signalling to microglia. This approach 
would be rather complex, as MMPs seem to play a detrimental and a beneficial role in the 
pathophysiology of the CNS (Yong, 2005). However, it would be interesting to assess the 
involvement of metalloproteinases in regulating the MAG-microglial signalling. 
Nevertheless, these results are the first to show that a single myelin protein can trigger a 
microglial inflammatory response when presented in a non-physiological context. 
 
5.4 In vivo relevance of MAG in regulating microglial behaviour 
The conditions under which the microglial cells are in a resting or activated state have 
been studied extensively (Raivich et al., 1999; van Rossum and Hanisch, 2004). Changes 
in the microglial status from quiescent to activated in neuropathological cases such as 
laser-induced brain injury are often accompanied by microglial movement towards the 
lesion site (Nimmerjahn et al., 2005). However, having remarkably motile processes, 
even under healthy conditions, microglial cells are able to control the status of the CNS 
environment (Davalos et al., 2005; 2008; Nimmerjahn et al., 2005). This microglial 
process outgrowth should be controlled and restricted in terms of space, as any abnormal 
signalling to microglia would lead to the activation and further response of the adaptive 
immune system (Aloisi, 2001). Based on the working hypothesis MAG plays a spatially 
inhibitory role in microglial process outgrowth by restricting their access to the axon-
myelin unit. Therefore, anaesthetized CXCR-EGFP transgenic mice (Jung et al., 2000) 
were used to visualize the motility of microglia in the spinal cord (Fig.19). Monitoring 
the microglial behaviour with reference to YFP-expressing neurons in vivo (Winter et al., 
2007), the microglial behaviour was altered in the absence of MAG compared to the 
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wild-type controls. Interestingly, there was a high number of microglia with fewer 
processes and in close association with the axons (Fig.19F). Additionally, the spatial 
distribution of microglial cells and their processes was altered in the absence of MAG. 
More precisely, there are many microglia that contact each other in the MAG-deficient 
mice, a feature that is only observed under pathological stimuli, such as laser-induced 
lesion, in the wild-type mice (data not shown). Therefore, I have hypothesized that the 
lack of the inhibitor (MAG) in vivo leads to the exposure of molecules that “attract” the 
microglial somata and/or processes. These “attractants” that I resemble to “hot glue”, are 
possibly more exposed due to the lack of the inhibitor in the MAG-deficient mice and as 
a result the microglial process distribution is altered in the MAG-deficient mice.  
 
Regarding the in vivo data presented in this work as a whole, I suggest that, as a surface 
presented molecule or in low amounts shed from the membrane, MAG plays an 
inhibitory-repellent role in restricting the microglial processes from perturbing the axon-
myelin unit. This “control mechanism” is important, as any interference would lead 1) to 
the loss of neuronal function and 2) possibly to further microglial signalling to the 
adaptive immune system. Thus, I suggest that the MAG-microglial signalling is 
important for restricting the microglial process outgrowth and additionally might act as a 
signal to microglia that the integrity of the CNS tissue is normal. According to the current 
knowledge, this study is the first to show that the microglial behaviour is affected in 
young MAG-deficient mice.  
 
5.5 The significance of MAG in the microglial behaviour in pathology 
Is microglial-MAG signalling involved in pathology? I first investigated whether the 
receptor complex known to mediate the myelin-elicited inhibition and shown in this study 
to be expressed in microglia is regulated at the transcriptional level upon an activation 
signal. For that purpose, microglia were cultured and stimulated with LPS (Fig.8), a 
substance of the Gram-negative bacterial cell wall that activates microglia both in vitro 
and in vivo (Kloss et al., 2001). Interestingly, the Nogo-66 receptor complex was 
regulated upon activation; NgR1 and Lingo-1 were upregulated, no change regarding the 
NgR2 expression, while the rest of the receptors were downregulated (Fig.8B). This 
regulation is partially in agreement with the regulation of the NgR, Troy and Lingo-1 
protein expression in the case of MS (Satoh et al., 2005; 2007). In this study, all three 
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proteins were upregulated in MS tissue and compared to healthy patients. The apparent 
difference regarding the regulation of Troy between this study and the studies mentioned 
above might be due to differences in 1) the nature of the activation signal and microglial 
response: LPS versus strong autoimmune response, 2) the organisms analyzed: mice 
versus humans, 3) the level of analysis: mRNA versus protein and 4) the material used 
for the analysis: microglia in culture versus brain tissue. Taken together, the current 
experiment showed that microglia responded to LPS and the transcription of the Nogo 
receptor complex was regulated upon activation. 
 
Microglia respond to a number of stimuli in order to protect the CNS tissue (van Rossum 
and Hanisch, 2004). In this study it was also shown that there is a microglial response 
regarding the expression of the Nogo receptor complex upon activation. Thus, I asked 
whether MAG-microglial signalling interferes with, i.e. ameliorates or antagonizes other 
activating pathways such as the Toll-like receptor (TLR) pathways. Consequently, 
different TLR agonists, such as the Pam3SK4 (a TLR1/2 agonist), the LPS (a TLR4 
agonist) and the MALP-2 (a TLR2/6 agonist) that involve different TLRs, were applied 
to the microglia/CHO co-cultures and the supernatants were analyzed for the release of 
cyto- and chemokines (Fig.17). This system failed to yield any concrete results, as there 
was no LPS- or Pam3SK4- mediated microglial activation, suggesting that there might be 
other molecules expressed at the surface of the CHO cells that interfere with the 
signalling. Although MALP-2 induced a microglial response, there was no obvious 
difference between the presence and absence of MAG. Consequently, the same 
experiment was repeated in the absence of the interfering “background” of the CHO cells 
by using the recombinant extracellular domain of MAG as a substrate (Fig.18). 
Surprisingly, microglia cultured on the MAG substrate showed an inflammatory response 
even in the absence of any stimulus. This might have been due to traces of unbound 
soluble MAG, which is now known (Fig.16) that it can lead to microglial inflammatory 
responses when presented in critical amounts. Nevertheless, the addition of the TLR 
agonists LPS, MALP-2 and Pam3SK4 in the presence or absence of MAG led to an 
additive microglial response. These results suggest that the MAG-microglial signalling 
probably does not interfere with the TLR 1, 2, 4 and 6 pathways in vitro. 
 
The possible involvement of the MAG-mediating microglial signalling under 
pathological conditions was assessed in vivo. One such case in the CNS is the Wallerian 
 94
DISCUSSION 
degeneration (WD) (Vargas and Barres, 2008). This term describes the progressive 
degeneration of the distal part of the nerve after transection. The slower rate of WD in the 
CNS compared to PNS has been attributed to poor myelin removal (Vargas and Barres, 
2007). Microglia phagocytose CNS myelin at a slower rate than macrophages 
phagocytose PNS myelin, suggesting that local factors affect their phagocytic 
performance (Kuhlmann et al., 2002). Therefore, the microglial behaviour was tested in 
the absence of MAG in a model of WD. In mice lacking PLP, the main myelin protein of 
the CNS myelin WD and microglial activation was previously shown (Griffiths et al., 
1998). In this work, it was shown that the absence of MAG triggered the formation of 
foamy microglial cells, indicating abnormal myelin phagocytosis (Fig.21A). These 
results suggest that MAG acts as an inhibitor and, in the case of activation signals, such 
as WD, the absence of MAG may facilitate the removal of myelin by activated microglia.  
 
Another common pathological situation in the CNS where microglia participate in the 
first defence line is the presence of bacteria. The model used experimentally to study the 
pathways involved is the administration of LPS ( Aravalli et al., 2007). Even the 
intraperitoneal injection of LPS in mice can lead to microglial activation in the brain 
(Kloss et al., 2001). Therefore, LPS was injected intraperitoneally in MAG-deficient and 
wild-type mice and the microglial response was analyzed at different time points. Indeed, 
as ascertained by Mac-3 staining, there was a difference between the MAG-deficient and 
wild-type mice in terms of their microglial response, a marker of microglial activation 
(Fig.22). Overall, the LPS-injected MAG-deficient mice had a higher number of Mac-3 
positive cells in the white matter of the cerebellum compared to the LPS-injected wild-
type mice. Additionally, a number of LPS-injected MAG-deficient mice became sick and 
died after 72 hrs, although the number of animals analyzed was not sufficient to draw any 
conclusions. The intraperitoneal administration could lead to the response of the 
peripheral immune system, such as the macrophages (Forestier et al., 1999). Additionally 
it is known that MAG signals to macrophages (Fry et al., 2007). Therefore, the sickness 
and, indirectly, the microglial response observed after LPS administration in the MAG-
deficient mice might also be due in part to mechanisms and signalling that involve the 
macrophages. Nevertheless, these preliminary results suggest that the presence of MAG 
might play an important role in regulating the microglial response under pathological 
conditions, such as inflammation, as the absence of MAG led to enhanced microglial 
activation and to severe clinical symptoms of the mice.  
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Multiple sclerosis is another pathological condition in the central nervous system, where 
microglia have a detrimental and a beneficial role ( McQualter and Bernard, 2007). One 
of the features of multiple sclerosis is myelin destruction. Therefore, based on the 
working hypothesis, the myelin-associated inhibitors are more exposed and, additionally, 
the upregulation of MMPs (see above) might lead to the increased exposure of dMAG. 
Therefore, the impact of MAG-microglial signalling was investigated in the MS model in 
rodents, i.e. experimental allergic encephalomyelitis (EAE). Wild-type and MAG-
deficient mice were subjected to EAE (material kindly provided by P.Calabresi) and 
analyzed at different time points after immunization. One of the drawbacks of this model 
is that multiple sclerosis symptoms, such as demyelination and cellular infiltration, are 
only developed in the spinal cord. David and colleagues proposed that the MAG/NgR 
pathway might be involved in the valuable spatial restriction of microglia/macrophages in 
the lesion site in the case of MS (David et al., 2008). Therefore, the microglial activation 
was analyzed in the spinal cord of immunized mice of both genotypes. As this model 
leads to microglial activation and macrophage infiltration, and it is difficult to distinguish 
between the two cell types, the analysis involved both cell types. Thus, first the 
distribution of cell infiltration was examined with reference to myelinating areas, as 
ascertained using Luxol-fast blue staining. It was striking that there were signs of cellular 
infiltration in the MAG-deficient mice as early as 1d.p.i (Fig.23), while the clinical 
symptoms did not start earlier than 10-12 d.p.i with this model. Another interesting 
observation was that there was only a persistent loss of myelin 5 months post-
immunization in the MAG-deficient mice. These results, although preliminary, suggest 
that the MAG-microglial signalling is indeed important and might indirectly regulate the 
response of the adaptive immune system.  
 
The overall microglial activation in the EAE model was examined and surprisingly, this 
was different between the two genotypes. There was an early microglial response in the 
absence of MAG at 1d.p.i (Fig.24B), while later on massive microglial activation was 
observed only in the EAE-induced wild-type mice (Fig.24). One of the drawbacks of the 
EAE model is that there is a great variability between the animals induced, therefore a 
larger number of animals should be analyzed. It is also necessary to stain with other 
microglial/macrophage markers, as well as with T cell markers, in order to obtain a 
complete picture of the importance of MAG signalling in the context of pathology and its 
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effect on the different cell types. Taken together, these preliminary results suggest that 
the MAG signalling plays a role in regulating the microglial activity. 
 
5.6 Astrocytes and myelin-associated inhibitors 
Astrocytes also have numerous processes (Nedergaard et al., 2003) that may potentially 
interfere with important structures such as the axon-myelin unit. Consequently, the 
possibility that myelin-associated inhibitors might also target astrocytes was examined in 
this study. An approach similar to the one used for microglia was adopted. First, the 
expression of the Nogo receptors and co-receptors was assessed in purified astrocytes. 
Using FACS-sorted astrocytes from transgenic GFAP-EGFP mouse brains (Nolte et al., 
2001), the expression of the entire Nogo receptor complex was detected at the mRNA 
level (Fig.25). These results support previous studies, showing the protein expression of 
NgR, Troy and Lingo-1 in astrocytes in human tissue (Satoh et al., 2005; 2007). 
Therefore, the role of MAG and Nogo-A in regulating the astrocytic morphology was 
further assessed by using MAG-expressing CHO cells and Nogo-A-expressing 3T3 cells 
co-cultured with astrocytes. Indeed, the astrocytes had fewer and shorter processes and 
the protoplasmic type was the dominant type when co-cultured with MAG-CHO cells. 
However, in the case of the Nogo-A-expressing cells, additional Nogo-A-negative contol-
3T3 cells would be needed before firmly stating the absence of any other protein effect 
on astrocytic process outgrowth. In contrast, there was no obvious effect in the astrocytic 
morphology induced by Nogo-A (Fig.26). Taken together, these preliminary results 
showed an inhibitory effect of MAG on astrocytes. MAG signalling leads to RhoA 
activation in neurons (Niederost et al., 2002), in macrophages (Fry et al., 2007) and in 
microglia, as shown in this study. The astrocytic morphology is also regulated by the 
small GTPase Rho (Holtje et al., 2005), therefore it is possible that the same intracellular 
pathways related to the myelin-associated inhibitors are involved in astrocytes. 
 
To test whether there is an effect of the potential MAG-astrocytic signalling in vivo, the 
EAE-induced mice were analyzed for reactive astrogliosis. There was no difference in the 
extent of the reactive astrogliosis between the wild-type and MAG-deficient mice 
(Fig.27). The physiological role of this interaction, however, may become more obvious 
in vivo in different models than EAE, which causes strong inflammatory responses, and 




5.7 What is the impact of this study for the neuronal regeneration? 
The in vitro and in vivo data presented in this study support the notion of a novel role of 
MAG in inhibiting and controlling microglial process outgrowth and possibly the 
microglial status. Surface-presented MAG and small amounts of dMAG shed from the 
membrane prevents the microglial processes from interfering with the axon-myelin unit 
(Fig.28A). In the case of pathology, such as inflammation caused by LPS or autoimmune 
responses, MAG can be more exposed either because of myelin destruction or the 
elevation of metalloproteinases that shed MAG from the membrane leading to microglial 
activation (Fig.28B).  
 
The preliminary results presented in this work suggest that the presence of MAG seems 
to control the microglial response as, in the absence of MAG in the Wallerian 
degeneration model of PLP-deficient mice, activated microglia were found to “attack” the 
myelin sheath and to invade the periaxonal space (Ian Griffiths, unpublished data) 
(Fig.28C). Further investigation is necessary to test whether this role is also applicable to 
other disease models, such as injury. Interestingly, in this study there was no effect of 
Nogo-A on microglia, suggesting principle differences compared to the molecules 
involved in inhibiting neurons. In this respect, it would be also interesting to assess the 
function of other myelin-associated inhibitors, such as oligodendrocyte-myelin 





































Figure 28. Model of the MAG-to-
microglial signalling in the healthy 
and diseased CNS 
MAG, and possibly other myelin-
associated inhibitors, either surface 
presented or shed from the membrane 
by matrix metalloproteinases (MMPs), 
prevents microglial processes from 
interfering with the axon-myelin unit 
(A). In case of pathological stimuli, 
such as injury, LPS infection, 
Wallerian degeneration, PLP-
deficiency or EAE that lead either to 
myelin degeneration or elevation of 
MMPs, more shed or surface-
presented MAG are exposed to 
microglia leading to their activation 
(B). In the absence of MAG, microglia 
attack the myelin sheath and invade 








One important approach to promote regeneration in the CNS after injury is to block the 
ligand/NgR complex (Grandpre et al., 2002) or the downstream RhoA signalling pathway 
(Dergham et al., 2002; Fournier et al., 2003). It is now known that this mechanism also 
regulates the microglial physiology; therefore, the beneficial effect for axonal 
regeneration might be detrimental to the microglial response. In another case of 
pathology, such as Wallerian degeneration, MAG and possibly the other myelin-
associated inhibitors might restrict the microglial phagocytosis, which suggests that an 




myelin removal after injury. Consequently, blocking the inhibitors with, for example, 
synthetic peptides might increase the phagocytosing abilities of microglia.  
 
The function of MAG and the other myelin-associated inhibitors in the CNS was only 
considered with respect to their negative effect on axonal outgrowth. Overcoming this 
inhibition and promoting axonal regeneration has been the main focus of many studies 
(Yiu and He, 2006; Chaudhry and Filbin, 2007). The involvement of this mechanism in 
the macrophage efflux from the basal lamina in the PNS (Fry et al., 2007) very recently 
extended the potential of this molecular machinery to non-neuronal cells. This study 
yielded new evidence that supports the notion that the myelin-associated inhibitory effect 
is beneficial in preventing the remarkably motile microglial processes from perturbing 
the axon-myelin unit under healthy conditions.  
 
In conclusion, this study suggests that the evolutionary emergence of myelin-associated 
inhibitors was beneficial for the protection of the axon-myelin unit in the complex 
nervous system of higher vertebrates that also possess a complex immune system. As this 
mechanism regulates both axonal regeneration and microglial activity, it is essential that 
we consider these effects are considered in planning the current and future regeneration 
and neuroprotective strategies to avoid any interference with the immune system that 
might lead to increased inflammation. 
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6. Summary and Conclusions 
Myelin-associated growth inhibitors, such as Nogo, MAG and OMgp, cause neuronal 
growth cone collapse and prevent the regeneration of CNS axons. In recent decades, a 
great amount of research has elicited the molecular mechanisms involved in neurite 
inhibition but little is known about the physiological function of these myelin-associated 
inhibitors. The working hypothesis was that the glial cells in the CNS might also be 
responsive to myelin inhibitors. 
 
I first assessed the expression of the Nogo receptors and co-receptors in FACS-isolated 
brain microglia and astrocytes. For this experiment, transgenic mice that express the 
enhanced green fluorescent protein (EGFP) under a specific microglial (CX3CR1) or 
astrocytic (GFAP) promoter were employed. This analysis revealed that most of the key-
players involved in myelin-associated inhibition are expressed in microglia and 
astrocytes. 
 
Furthermore, the effect of MAG and Nogo-A on microglia and astrocytes in vitro was 
assessed by using MAG expressing CHO cells and Nogo-A-expressing 3T3 cells as 
feeder layers. Indeed, the microglial and the astrocytic processes were inhibited in the 
presence of MAG, but not Nogo-A. In addition, NgR1-deficient microglia and the Rho-
associated kinase inhibitor Y27632 were used in the same assay to evaluate the 
involvement of NgR1 and RhoA in the MAG-microglial signalling. In these experiments, 
I showed that NgR1 is partially involved, while the inhibition of the RhoA could rescue 
the microglial process inhibition completely.  
 
To confirm these results, a stripe assay was used where recombinant MAG lanes were 
alternated with PLL stripes as a substrate for microglial growth. This experiment 
confirmed the inhibitory role of MAG in microglia and the partial involvement of the 
NgR1. Additionally, using the same assay with a shorter mutant form of MAG, I could 
show that the MAG domain responsible for the microglial process inhibition lies within 
the Ig domain 1-3. Furthermore, I demonstrated that dMAG, the extracellular domain of 
MAG that serves as a sign of myelin destruction, has a different role when presented in 
high amounts in the medium by acting as a signal that leads to microglial activation.  
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By using two-photon in vivo microscopy under physiological conditions, the roaming 
behaviour of microglia was observed. Surprisingly, the absence of MAG led to an altered 
microglial process distribution and increased microglial association with the axons. When 
the CNS tissue was challenged, either by the absence of the major myelin proteolipid 
protein or by inflammation stimuli, such as the lipopolysaccharide administration or the 
EAE, the microglial response was altered in the absence of MAG, supporting the idea 
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